CA2507664C - Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product - Google Patents

Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product Download PDF

Info

Publication number
CA2507664C
CA2507664C CA2507664A CA2507664A CA2507664C CA 2507664 C CA2507664 C CA 2507664C CA 2507664 A CA2507664 A CA 2507664A CA 2507664 A CA2507664 A CA 2507664A CA 2507664 C CA2507664 C CA 2507664C
Authority
CA
Canada
Prior art keywords
gene
seq
ala
mammalian cells
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2507664A
Other languages
French (fr)
Other versions
CA2507664A1 (en
Inventor
Barbara Enenkel
Kerstin Sautter
Ralf Otto
Jurgen Fieder
Klaus Bergemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10330686A external-priority patent/DE10330686A1/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to CA2706873A priority Critical patent/CA2706873C/en
Publication of CA2507664A1 publication Critical patent/CA2507664A1/en
Application granted granted Critical
Publication of CA2507664C publication Critical patent/CA2507664C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01095—Kanamycin kinase (2.7.1.95), i.e. neomycin-kanamycin phosphotransferase

Abstract

The invention relates to novel modified neomycin phosphotransferase genes and the use thereof in a selection method for high-producing recombinant cells.
The invention also relates to expression vectors containing a modified neomycin phosphotransferase gene and a gene of interest in a functional bond with a heterologous promoter, and a method for producing heterologous gene products by using said expression vectors.

Description

81844fft.208 Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired Gene product Scope of the Invention The invention relates to new modified neomycin-phosphotransferase genes and their use in selection methods for high-producing recombinant cells.
1 o Accordingly, the present invention also relates to new expression vectors which contain a modified neomycin-phosphotransferase gene, preferably combined with a gene of interest functionally linked to a heterologous promoter. The invention further relates to methods of preparing heterologous gene products using the corresponding high-producing recombinant cells.
Background to the Invention Mammalian cells are the preferred host cells for the production of complex biopharmaceutical proteins as the modifications carried out post-2 o translationally are compatible with humans both functionally and pharmacokinetically. The main relevant cell types are hybridoma, myeloma CHO (Chinese Hamster Ovary) cells and BHK (Baby Hamster Kidney) cells.
The cultivation of the host cells is increasingly carried out under serum- and protein-free production conditions. The reasons for these are the 2 5 concomitant cost reduction, the reduced interference in the purification of the recombinant protein and the reduction in the potential for the introduction of pathogens (e.g. prions and viruses). The use of CHO cells as host cells is becoming more widespread as these cells adapt to suspension growth in serum- and protein-free medium and are also regarded and accepted as safe 3 o production cells by the regulatory authorities.

In order to produce a stable mammalian cell line which expresses a heterologous gene of interest (GOI), the heterologous gene is generally inserted in the desired cell line together with a selectable marker gene such as e.g. neomycin phosphotransferase (NPT) by transfection. The s heterologous gene and the selectable marker gene can be expressed in a host cell starting from one individual or separate cotransfected vectors. Two to three days after transfection the transfected cells are transferred into medium containing a selective agent, e.g. G418 when using neomycin phosphotransferase-gene (NPT gene), and cultivated for some weeks under 1 o these selective conditions. The emerging resistance cells which have integrated the exogenous DNA can be isolated and investigated for expression of the desired gene product (of the GOI).
A major problem in establishing cell lines with a high expression of the 15 desired proteins arises from the random and undirected integration of the recombinant vector into transcriptionally -active or -inactive loci in the host cell genome. As a result a population of cells is obtained which have completely different expression rates of the heterologous gene, the productivity of the cells generally following normal distribution. In order to 2 o identify cell clones which have a very high expression of the heterologous gene of interest it is therefore necessary to examine and test a large number of clones, which is time consuming, labour intensive and expensive.
Improvements to the vector system used for transfection therefore set out to increase the proportion of high producers in the transfected cell population by 2 s suitable selection strategies and thereby reduce the expenditure and work involved in clone identification. The development of such an expression system is the subject of the present invention.
The amino glycoside-3'-phosphotransferase II enzyme (neomycin-3 o phosphotransferase) (EC27195) the gene of which is transposon 5-associated in Escherichia coli is used as a selectable marker in a number of organisms (e.g. bacteria, yeasts, plants and mammalian cells). This enzyme confers resistance to various aminoglycoside antibiotics such as neomycin, kanamycin and 6418, by inactivating the antibiotics by transferring the terminal phosphate from ATP to the 3' hydroxyl group of the aminohexose ring I. In addition to the wild-type neomycin phosphotransferase some s mutants are known which have reduced phosphotransferase activity and hence reduced resistance to aminoglycoside antibiotics in bacteria (Blazquez et al., 1991; Kocabiyik et al., 1992; Yenofsky et al., 1990) and in slices of leaf from tobacco (Yenofsky et al., 1990).
to One of these mutants (GIu182Asp) was used as a marker for selecting embryonic stem cells, the neomycin phosphotransferase gene being integrated into the c-myc gene by targeted homologous recombination (gene targeting) (Hanson et al., 1995). The authors restrict themselves to the use of the modified enzyme for gene targeting.
Patent application WO 99/53046 describes the expression of a modified neomycin phosphotransferase gene (Asp261 Asn) in production-relevant mammalian cells. The authors describe a non-cloning method for expression of a gene of interest in mammalian cells. By cotransfection of the cells with 2 o three individual DNA fragments which code for a promoter element, a gene of interest and a selectable marker coupled with an IRES ("Internal ribosomal entry site") element, it is possible to deliberately grow cells, under selection pressure, in which all three DNA fragments are combined as a functional bicistronic transcription unit (promoter gene of interest-IRES-neomycin-phosphotransferase gene). The arrangement of the elements only occurs in the transfected cell, so that only a few cells show the correct arrangement of the elements. Moreover, after gene amplification, using an amplifiable selectable marker, no high producing clones can be generated. After repeated selection and gene amplification the cells generated exhibited at 3 o most 6 pg of protein per cell per day (6pglcell/day).
None of the publications discloses modified neomycin phosphotransferase genes with particular suitability for the preparation of a high expression vector system for mammalian cells which makes it possible to develop high producing cells in order to prepare recombinant biopharmaceutical proteins which contain one or more complete functional transcription units both for one or more genes of interest and also for a modified neomycin phosphotransferase gene with reduced antibiotic resistance. The DNA
construct described in WO 99/53046 contains only a promoter-less neomycin gene functionally linked to the gene for dihydrofolate reductase (DHFR).
to There is therefore a need to make suitable modified neomycin phosphotransferase genes available, particularly for the development of corresponding high expression vector systems for biopharmaceutical processes. The problem of the present invention was therefore to provide corresponding new modified neomycin phosphotransferase genes, expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter, a method of selection for high producing recombinant cells, preferably for mammalian cells, and a process for producing heterologous gene products.
Surprisingly, within the scope of the present invention, it has been possible to produce and identify new modified highly selective neomycin phosphotransferase genes which are characterised by their particular suitability for the selection of high producing cells.
Summary of the Invention The present invention provides new modified neomycin phosphotransferase genes. Surprisingly, it has been found that an enrichment of transfected 3 o mammalian cells with high expression rates of the co-integrated gene of interest could be achieved by using the modified neomycin phosphotransferase genes described hereinafter as selectable markers.
Compared with the use of the wild-type neomycin phosphotransferase as selectable marker, after transfection with one of the new neomycin phosphotransferase genes according to the invention the cells exhibited a productivity of a protein (an antibody) which was increased by a factor 1.4 to 14.6.
The modified neomycin phosphotransferase genes according to the invention are preferably mutants which code for a different amino acid from the wild-type gene at amino acid position 91, 182, 198, 227, 240 or 261. In a io preferred embodiment the neomycin phosphotransferase gene according to the invention is the mutant GIu182G1y, GIu182Asp, Trp91Ala, Va1198G1y, Asp227A1a, Asp227Va1, Asp227G1y, Asp261Asn, Asp261G1y or Phe24011e.
For selecting high producing mammalian cells it has proved particularly suitable to use the mutants Trp91Ala, Asp227Va1, Asp261Asn, Asp261 Gly and Phe24011e, while the mutants Asp227Va1 and Asp261 Gly in turn gave cell clones with the highest productivity and are therefore particularly preferred.
The high-producing cells were obtained by the use of a eukaryotic expression vector which contains a heterologous gene of interest functionally linked to a 2 o heterologous promoter and a modified neomycin phosphotransferase gene according to the invention. The expression vector preferably contains other regulatory elements, e.g, one or more enhancers functionally linked to the promoter or promoters. Expression vectors are also preferred which additionally contain a gene for a fluorescent protein which is functionally 2 5 linked to the gene of interest and the heterologous promoter, preferably via an internal ribosomal entry site (IRES), which enables bicistronic expression of the gene which codes for a fluorescent protein and of the gene which codes for a protein/product of interest, under the control of the heterologous promoter. Particularly suitable are expression vectors in which the 3 o heterologous gene of interest is under the control of the ubiquitin/S27a promoter.
The invention also relates to expression vectors which instead of the gene of interest contain a multiple cloning site for incorporating such a gene, i.e. a sequence section with multiple recognition sequences for restriction endonucleases.
In another aspect the invention relates to recombinant mammalian cells which contain one of the abovementioned modified neomycin phosphotransferase genes according to the invention. In addition the present invention relates to recombinant mammalian cells which have been 1o transfected with one of the expression vectors according to the invention.
These are preferably recombinant rodent cells, of which recombinant hamster cells such as e.g. CHO cells or BHK cells are particularly preferred. In another preferred embodiment the said recombinant cells are additionally transfected with the gene for an amplifiable selectable marker, e.g. with the gene of dihydrofolate reductase (DHFR).
The invention also relates to a process for enriching recombinant mammalian cells which express a modified neomycin phosphotransferase gene, characterised in that (i) a pool of mammalian cells is transfected with a gene 2 o for a modified neomycin phosphotransferase, which has only 1 to 80%, preferably only 1 to 60%, more preferably only 1.5 to 30%, most preferably only 1.5 to 26% of the activity and/or one of the modifications described above; (ii) the mammalian cells are cultivated under conditions which allow expression of the modified neomycin phosphotransferase gene; and (iii) the 2 s mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells, and gives preference to the growth of those cells which express the neomycin phosphotransferase gene.
3 o The invention also relates to a process for the expression of at least one gene of interest in recombinant mammalian cells, characterised in that (i) a pool of mammalian cells is transfected with at least one gene of interest and one gene for a modified neomycin phosphotransferase which exhibits only 1 to 80%, preferably only 1 to 60°!°, more preferably only 1.5 to 30%, most preferably only 1.5 to 26% of the activity and/or one of the modifications described above; (ii) the cells are cultivated under conditions which allow expression of the gene or genes of interest and the modified neomycin phosphotransferase gene; (iii) the mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells and gives preference to the growth of those cells which express the neomycin phosphotransferase gene; and (iv) the protein or 1 o proteins of interest is or are obtained from the mammalian cells or from the culture supernatant.
The present invention further relates to a process for obtaining and selecting recombinant mammalian cells which express at least one heterologous gene of interest, which is characterised in that (i) recombinant mammalian cells are transfected with an expression vector according to the invention which in addition to the gene of interest and the modified neomycin phosphotransferase gene codes for a fluorescent protein; (ii) the mammalian cells are cultivated under conditions which allow expression of the gene or 2 o genes of interest, the gene which codes for a fluorescent protein and the modified neomycin phosphotransferase gene; (iii) the mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells and gives preference to the growth of those cells which express the neomycin phosphotransferase gene;
2 5 and (iv) the mammalian cells are sorted by flow-cytometric analysis.
If the mammalian cells have additionally been transfected with a gene for an amplifiable selectable marker gene, e.g. the DHFR gene, it is possible to cultivate the mammalian cells under conditions in which the amplifiable 3 o selectable marker gene is also expressed, and to add to the culture medium a selecting agent which results in amplification of the amplifiable selectable marker gene.

Preferably, the processes according to the invention are carried out with mammalian cells which are adapted to growth in suspension, i.e. with mammalian cells which are cultivated in a suspension culture. Other s embodiments relate to processes in which the mammalian cells, preferably those which are adapted to growth in suspension, are cultivated under serum-free conditions.
Description of the Figures io Figure 1 shows a diagrammatic representation of the base vectors used to express the recombinant proteins in CHO-DG44 cells. "PlE" is a combination of CMV enhancer and hamster-ubiquitin/S27a promoter, "P" on its own indicates a promoter element and "T" is a termination signal for transcription, which is needed for the polyadenylation of the transcribed mRNA. The position and direction of transcription initiation within each transcription unit is indicated by an arrow. For cloning the heterologous genes a sequence region with multiple cutting sites for restriction endonucleases (multiple cloning sites - MCS) is inserted after the promoter element. The amplifiable 2o selectable markerdihydrofolate reductase is abbreviated to "dhfr" and the selectable marker neomycin phosphotransferase is abbreviated to "npt" (npt wild-type or npt mutant). The "IRES" element coming from the encephalomyocarditic virus acts an internal ribosomal entry site within the bicistronic transcription unit and enables translation of the following green 25 fluorescent protein "GFP".
Figure 2 shows a diagrammatic view of the eukaryotic expression vectors which code for a single-chain protein (Figure 2A) or for a subunit of a monoclonal antibody (Figure 2B) and are used to transfect CHO-DG44 cells.
30 "P/E" is a combination of CMV enhancer and hamster ubiquitin/S27a promoter, "P" on its own is a promoter element and "T" is a termination signal for the transcription which is needed for the polyadenylation of the transcribed mRNA. The position and direction of transcription initiation within each transcription unit is indicated by an arrow. The amplifiable selectable marker dihydrofolate reductase is abbreviated to "dhfr" and the selectable marker neomycin phosphotransferase is abbreviated to "npt". The NPT mutants E182G (SEQ ID N0:3), E182D (SEQ ID N0:19), W91A (SEQ ID N0:5), D190G (SEQ ID N0:23), V198G (SEQ ID N0:7), D208G (SEQ ID N0:25), D227A (SEQ ID N0:9), D227V (SEQ 1D N0:11 ), D227G (SEQ ID N0:21 ), D261G (SEQ ID N0:13), D261N (SEQ ID N0:15) and F2401 (SEQ ID N0:17) contain a point mutation which results in a modified amino acid (given in 1-to letter code) at the position indicated. The IRES element originating from the encephalomyocarditis virus acts as an internal ribosomal entry site within the bicistronic transcription unit and permits translation of the following green fluorescent protein "GFP". "MCP-1" codes for the Monocyte Chemoattractant Protein-1, whereas "HC" and "LC" code for the heavy and light chains, respectively, of a humanised monoclonal IgG2 antibody.
Figure 3 shows the part of the sequence of the neomycin phosphotransferase (npt) gene in which the point mutations have been inserted by PCR with mutagenic primers. The capital letters indicate the 2 o nucleotide sequence of the npt coding region whereas the small letters indicate the flanking non-coding nucleotide sequences. The amino acid sequence predicted from the nucleotide sequence (3-letter code) is shown above the coding nucleotide sequence. Arrows indicate the direction, length and position of the primers used, the arrows with solid lines indicating the 2 s mutagenic forward primers, the broken lines indicating the mutagenic reverse primers, the dotted lines indicating the primers Neofor5 (SEQ ID N0:27) or Neofor2 (SEQ ID N0:29) located upstream of the npt gene or the mutation site, respectively, and the dot-dash line indicating the primers Neorev5 (SEQ
ID N0:28) or IC49 (SEQ ID N0:30) located downstream of the npt gene or 3 o the mutation site, respectively. The nucleotides exchanged with respect to the wild-type sequence are emphasised above and below the arrows.

- to -Figure 4 shows conserved domains and the position of the inserted NPT
mutations within the NPT amino acid sequence. On the basis of sequence homologies between different aminoglycoside-modified enzymes, different conserved domains were identified within the NPT protein sequence (shown in grey) The three motifs in the C-terminal region of the enzyme obviously have special functions. Motifs 1 and 2 are presumably involved in the catalytic transfer of the terminal phosphate in the ATP catalysis or the nucleotide binding, whereas motif 3 is thought to have a function in the ATP
hydrolysis and/or the change in conformation in the enzyme-aminoglycoside to complex. Amino acids which occur in at least 70% of the aminoglycoside-modifying enzymes are emphasised in bold type. The singly underlined amino acids are assigned to the same group on the basis of their similarity and occur in at least 70% of the aminoglycoside-modifying enzymes. Amino acids marked with an asterisk indicate the position of the mutation sites.
Abbildung 5 shows the influence of the NPT mutations on the selection of stably transfected MCP-1-expressing cells. For this, CHO-DG44 cells were transfected with the vectors pBIN-MCP1, pKS-N5-MCP1 and pKS-N8-MCP1 (Fig. 2A), which contained as selectable marker either the NPT wild-type (WT) or the NPT mutants G1u182Asp and Asp227G1y. For selecting stably transfected cells, 400 pg/mL or 800 Ng/mL of 6418 was added to the medium as a selective agent. The concentration in the cell culture supernatant of the recombinant protein MCP-1 produced was determined by ELISA and the specific productivity per cell and per day was calculated. The bars represent 2 5 the averages of the specific productivity or of the titre of 18 pools from cultivation in 6-well dishes.
In Figure 6 the influence of the NPT mutations on the selection of stably transfected mAb expressing cells was investigated. For this, CHO-DG44 cells 3 o were transfected with the plasmid combinations pBIDG-HC/pBIN-LC (NPT-wild-type), pBIDG-HC/pKS-N5-LC (NPT mutant GIu182Asp) or pBIDG-HC/pKS-N8-LC (NPT mutant Asp227G1y) (Fig. 6A) or with the combinations pBIDG-HC/pBIN-LC (NPT- wild-type), pBIDG-HC/pBIN1-LC (NPT mutant GIu182G1y), pBIDG-HC/pBIN2-LC (NPT mutant Trp91Ala), pBIDG-HC/pBIN3-LC (NPT mutant Va1198G), pBIDG-HC/pBIN4-LC (NPT mutant Asp227A1a), pBIDG-HC/pBINS-LC (NPT mutant Asp227Va1), pBIDG-HC/pBIN6-LC (NPT mutant Asp261G1y), pBIDG-HC/pBIN7-LC (NPT mutant Asp261Asn) or pBIDG-HC/pBINB-LC (NPT mutant Phe24011e) (Fig. 6B) which differ from one another only in the NPT gene (wild-type or mutant) used as a selectable marker. The concentration in the cell culture supernatant of the recombinant monoclonal IgG2 antibody produced was determined by ELISA
z o and the specific productivity per cell and per day was calculated. In all, 5 to 9 pools were set up for each vector combination. The bars represent the averages of the specific productivity or of the titre of all the pools in the Test from 6 cultivation runs in 75cm2 flasks. To calculate the relative titres or the relative specific productivities the averages of the pools selected with the NPT wild-type gene were taken as 1.
Figure 7 shows the enrichment of cells with a higher GFP expression in transfected cell pools by using the NPT mutants according to the invention as selectable markers. For this, CHO-DG44 cells were transfected with the 2 o plasmid combinations pBIDG-HCIpBIN-LC (NPT-wild-type), pBIDG-HC/pKS-N5-LC (NPT mutant GIu182Asp), pBIDG-HCIpKS-N8-LC (NPT mutant Asp227G1y), pBIDG-HC/pBIN1-LC (NPT mutant GIu182G1y),pBIDG-HC/pBIN1-LC (NPT mutant GIu182G1y), pBIDG-HC/pBIN2-LC (NPT mutant Trp91Ala), pBIDG-HC/pBIN3-LC (NPT mutant Va1198G), pBIDG-HC/pBIN4-LC (NPT mutant Asp227A1a), pBIDG-HC/pBINS-LC (NPT mutant Asp227Va1), pBIDG-HC/pBIN6-LC (NPT mutant Asp261G1y), pBIDG-HC/pBIN7-LC (NPT
mutant Asp261Asn) or pBIDG-HC/pBINB-LC (NPT mutant Phe24011e) (5 to 9 pools in each case), which differ from one another only in the NPT gene (wild-type or mutant) used as the selectable marker. Moreover, the pBIDG
3 o vectors also contained the GFP as marker gene. After 2 to 3 weeks' selection of the transfected cell pools in HT-free medium with the addition of 6418, the GFP fluorescence was measured by FACS analysis. Every graph, with the exception of the non-transfected CHO-DG44 cells used as a negative control, represents the average GFP fluorescence from the pools which had been transfected with the same plasmid combination.
Figure 8 shows the increase in the mAb productivity achieved by dhfr-mediated gene amplification taking as its example a cell pool which was obtained from the transfection of CHO-DG44 with the vector combination pBIDG-HC/pBIN-LC (NPT-wild-type) or pBIDG-HC/pBINS-LC (NPT mutant D227V). After the first selection in hypoxanthine/thymidine-free CHO-S-SFMII
to medium in the presence of 6418 a dhfr-mediated gene amplification was carried out by the addition of 100 nM and then 500 nM of MTX to the culture medium. The concentration of the mAb in the cell culture supernatant of the pools was determined by ELISA and the specific productivity per cell and per day (pg/cell*day) was calculated. Each data point represents the average of 15 six cultivation runs in 75cm2 flasks.
Figure 9 shows the enzyme activity of the NPT mutants according to the invention compared with the NPT wild-type, in a dot assay. For this, cell extracts were prepared from two different cell pools (pool 1 and 2) expressing 2 o mAb, which had been transfected and selected either with the NPT wild-type gene (SEQ ID N0:1 ) or with the NPT mutants E182G (SEQ ID N0:3), E182D
(SEQ ID N0:19), W91A (SEQ ID N0:5), V198G (SEQ ID N0:7), D227A
(SEQ ID N0:9), D227V (SEQ ID N0:11 ), D227G (SEQ ID N0:21 ), D261 G
(SEQ ID N0:13), D261 N (SEQ ID N0:15) and F2401 (SEQ ID
2s N0:17)GIu182Asp or Asp227G1y. Non-transfected CHO-DG44 cells were used as negative control. 6418 was used as the substrate in the phosphorylation assay. The extracts were filtered through a sandwich of P81 phosphocellulose and nitrocellulose membrane in a 96 well vacuum manifold.
Proteins phosphorylated by protein kinases and also non-phosphorylated 3 o proteins bind to the nitrocellulose, whereas phosphorylated and non-phosphorylated 6418 passes through the nitrocellulose and binds to the phosphocellulose (Fig. 9A). The radioactive signals were detected and quantified using a phosphoimager. The signals which had been obtained with 5 pg of extract were used to calculate the percentage enzyme activity.
The percentage enzyme activities denote the average of the NPT mutants from 2 cell pools expressing mAb, the enzyme activity of wild-type NPT being s taken as 100% (Fig. 9B).
Figure 10 shows the Northern Blot analysis of NPT expression and the number of NPT gene copies in the transfected cell pools. For this, total RNA
was prepared from two different cell pools expressing mAb which were to transfected and selected either with the NPT wild-type gene (SEQ ID N0:1 ) or with the NPT mutants E182G (SEQ ID N0:3), E182D (SEQ ID N0:19), W91A (SEQ ID N0:5), V198G (SEQ ID N0:7), D227A (SEQ ID N0:9), D227V (SEQ ID N0:11 ), D227G (SEQ ID N0:21 ), D261 G (SEQ ID N0:13), D261 N (SEQ ID N0:15) and F2401 (SEQ ID NO:17). Untransfected CHO-15 DG44 cells were used as the negative control. 30 :g of RNA was hybridised with a FITC-dUTP-labelled PCR product which comprised the coding region of the NPT gene. In all the transfected cells a specific singular NPT
transcript of about 1.3 kb was detected. In order to determine the npt gene copy number, in a dot blot analysis, genomic DNA was isolated from the 2 o abovementioned cell pools expressing mAb.
pg, 5 Ng, 2.5 Ng, 1.25 pg, 0.63 Ng and 0.32 pg of genomic DNA was hybridised with an FITC-dUTP-labelled PCRproduct which included the coding region of the NPT gene. Untransfected CHO-DG44 cells were used as the negative control. The plasmid pBIN-LC was used as the standard 2 5 (320 pg, 160 pg, 80 pg, 40 pg, 20 pg, 10 pg, 5 pg, 2.5 pg). The copy number of the npt genes in the cell pools was calculated using the standard series which had been determined from the signal intensities measured for the titrated plasmid-DNA.
3 o Figure 11 shows the isolation of high-expressing mAb cell pools by a GFP-based selection using FACS taking as the example two cell pools (cell pool 5 and 8). These cell pools, obtained from the co-transfection with the vectors - 1~ -pBID-HC and pBING-LC, were subjected to sequential GFP-based FACS
sorting. The concentration of the IgG2 antibody in the cell culture supernatant of the pools was determined by ELISA after each sorting step and the specific productivity per cell and per day (pglcell*day) was calculated. In all 6 sorts were done, and in each case the 5% of cells with the highest GFP
fluorescence were sorted out. Each data point represents the average of at least six cultivation runs in 75cm2 flasks.
Figure 12 shows the increases in mAb productivity achieved by combining a to GFP-based selection with an MTX amplification step taking as the example cell pools 5 and 8 (cf. Fig. 11 ). Two weeks after the co-transfection of CHO-DG44 with the vectors pBID-HC and pBING-LC the 5% of cells with the highest GFP fluorescence were sorted out from pools 5 and 8. Then dhfr-mediated gene amplification was carried out by adding 100 nM of methotrexate (MTX) to the culture medium. The concentration of the mAb in the cell culture supernatant of the pools was determined by ELISA and the specific productivity per cell and per day (pg/cell*day) was calculated. Each data point represents the average of at least six cultivation runs in 75cm2 flasks.
Figure 13 shows the correlation between the antibody productivity and the GFP fluorescence taking as the example cell pools 5 and 8 (cf. Fig. 11 ).
These cell pools were obtained by transfecting CHO-DG44 with the vector combination pBID-HC and pBING-LC. They were subjected to sequential 2 s GFP-based FACS sorting, and the 5% of cells with the highest GFP
fluorescence were sorted out. The concentration of the IgG2 antibody in the cell culture supernatant of the pools was determined by ELISA after each sorting step and the specific productivity per cell and per day (pg/cell*day) was calculated. Each data point represents the average of at least six 3 o cultivation runs in 75cm2 flasks.
Detailed Description of the Invention and Preferred Embodiments The following information on the amino acid positions relates in each case to the position of the amino acid as coded by the wild-type neomycin phosphotrasferase gene with SEQ ID N0:1. By a "modified neomycin phosphotransferase gene" is meant a nucleic acid which codes for a polypeptide with neomycin phosphotransferase activity, the polypeptide having a different amino acid from the wild-type protein at at least one of the amino acid positions described more fully in the specification which are homologous to the wild-type protein with SEQ ID N0:2. In this context the 1 o term "homologous" means that the sequence region carrying the mutation can be brought into correspondence with a reference sequence, in this case the sequence of the wild-type neomycin phosphotransferase according to SEQ ID N0:2, using so-called standard "alignment" algorithms, such as for example "BLAST" (Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.J. (1990) "Basic local alignment search tool." J. Mol. Biol. 215:403-410;
Gish, W. & States, D.J. (1993) "Identification of protein coding regions by database similarity search." Nature Genet. 3:266-272; Madden, T.L., Tatusov, R.L. & Zhang, J. (1996) "Applications of network BLAST server"
Meth. Enzymol. 266:131-141; Zhang, J. & Madden, T.L. (1997) 2 0 "PowerBLAST: A new network BLAST application for interactive or automated sequence analysis and annotation." Genome Res. 7:649-656;
Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search 2 5 programs", Nucleic Acids Res. 25:3389-3402). Sequences are in correspondence when they correspond in their sequence order and can be identified using the standard "alignment" algorithms.
The present invention provides new modified neomycin phosphotransferase 3 o genes and methods of preparing and selecting mammalian cell lines which allow a high expression of heterologous gene products, preferably biopharmaceutically relevant polypeptides or proteins The processes according to the invention are based primarily on the selection of cells which in addition to the gene of interest express a neomycin phosphotransferase gene according to the invention which gives the transfected cells a selective advantage over non-transfected cells. Surprisingly, it has been found that the s use of the modified neomycin phosphotransferase genes (mNPT genes) according to the invention described herein has a substantial selective advantage over the wild-type neomycin phosphotransferase gene (wtNPT
gene). This particularly relates to the use of mutants which have a lower enzyme activity compared with wtNPT.
to Modified Neomycin Phosphotransferase Genes According To The Invention 1t has proved particularly suitable to use modified NPT genes which code for an NPT having only 1 to 80%, preferably only 1 to 60% of the enzyme activity 15 of wtNPT. Preferred NPT mutants are those which have only 1 to 30% of the enzyme activity of wtNPT, while those which have only 1.5 to 26% of the enzyme activity of wtNPT are particularly preferred. The enzyme activity of an NPT can be determined for example in a dot assay as described in Example 4 and given as Method 5.
The term wild-type neomycin phosphotransferase refers to a neomycin phosphotransferase gene which codes for the aminoglycoside-3'-phosphotransferase II enzyme (EC 2.7.1.95) the gene of which is naturally transposon 5-associated in Escherichia coli, and contains for example the 2s amino acid sequence given in SEQ ID N0:2 or is coded by the nucleotide sequence given in SEQ ID N0:1. This enzyme gives resistance to various aminoglycoside antibiotics such as neomycin, kanamycin and 6418, by inactivating the antibiotics by the transfer of the terminal phosphate of ATP
to the 3' hydroxyl group of the amino hexose ring 1. The term wtNPT also refers 3 o to all NPTs which have a comparable enzyme activity to the NPT coded by SEQ lD N0:1. This includes in particular those NPTs in which the enzymatically active centre which catalyses the transfer of a terminal phosphate from ATP to a substrate is present in an identical or nearly identical conformation (Shaw et al., 1993; Hon et al; 1997; Burk et al., 2001 ) and thus has a comparable enzyme activity to an enzyme which contains the amino acid sequence of SEQ ID N0:2. A wtNPT has a comparable enzyme s activity if it exhibits about 81 to 150%, preferably 90 to 120% of the enzyme activity displayed by an NPT defined by SEQ ID N0:2, while the activity can be determined in the dot assay described in Example 4 and referred to as Method 5.
to Fundamentally preferred are mutants wherein the reduction in the enzyme activity compared with wtNPT is based on a modification of the amino acid sequence, e.g. on the substitution, insertion or deletion of at least one or more amino acids. Deletion, insertion and substitution mutants can be produced by "site-specific mutagenesis" and/or "PCR-based mutagenesis 15 techniques". Suitable methods are described for example by Lottspeich and Zorbas (1998)(Chapter 36.1 with other references).
Surprisingly, it has been found that if neomycin phosphotransferase mutants are used as selectable markers in which at least the amino acid tryptophan at 2 o amino acid position 91, the amino acid glutamic acid at amino acid position 182, the amino acid valine at amino acid position 198, the amino acid aspartic acid at amino acid position 227, the amino acid aspartic acid at amino acid position 261 or the amino acid phenylalanine at amino acid position 240 has been altered compared with wtNPT, it is possible to achieve particularly 2 5 effective enrichment of transfected mammalian cells with a high expression rate for the co-integrated gene of interest. Accordingly, mutants which affect the amino acids at positions 91, 182, 198, 227 and/or 240 are preferred.
Particularly advantageous are substitution mutants, i.e. mutants in which the amino acid occurring at this location in the wild-type has been replaced by 3 o another amino acid. Even more preferred are corresponding substitution mutants in which a change in the corresponding amino acid leads to a reduction in the enzyme activity compared with wt-NPT to 1 to 80%, - 1$ -preferably to 1 to 60%, more preferably to 1.5 to 30%, most preferably to 1.5% to 26%. Particularly preferred are modified NPT genes in which the amino acid 91, 227, 261 and/or 240 has been modified accordingly so that the enzyme activity compared with the wt-NPT is only 1 to 80%, preferably s only 1 to 60%, more preferably only 1.5 to 30%, most preferably only 1.5% to 26%. Most preferred is a substitution mutant in which the amino acid at amino acid position 227 has been modified in the form such that the enzyme activity of the modified NPT is less than 26%, preferably between 1 and 20%, more preferably between 1 and 16% compared with the wt-NPT.
According to another embodiment of the present invention, advantageous mutants are those which, by comparison with wtNPT, code for glycine, alanine, valine, leucine, isoleucine, phenylalanine or tyrosine at amino acid positions 91, 182 or 227. Moreover, the glutamic acid at amino acid position 1s 182 may also be replaced by aspartic acid, asparagine, glutamine or any other preferably negatively charged amino acid. Also preferred are modified NPT genes which, by comparison with wtNPT, code for glycine, alanine, leucine, isoleucine, phenylalanine, tyrosine or tryptophan at amino acid position 198. Also preferred are modified NPT genes which, by comparison 2o with wtNPT, code for glycine, alanine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, asparagine, glutamine or aspartic acid at amino acid position 261. In particular, it has been found that with the mutants GIu182G1y, GIu182Asp, Trp91Ala, Va1198G1y, Asp227A1a, Asp227Va1, Asp227G1y, Asp261 Gly, Asp261Asn and Phe24011e as selectable markers it 2 s was possible to achieve an enrichment of transfected mammalian cells with high expression rates of the co-integrated gene of interest, with the result that these mutants are particularly preferred. Still more preferred are the mutants Asp227Va1, Asp227G1y, Asp261G1y, Asp261Asn, Phe24011e and Trp91Ala, as the best enrichment rates are achieved using them. The utant Asp227Va1 is 3 o particularly preferred.

By contrast, the Asp190G1y and Asp208G1y mutants proved to be unsuitable markers for the selection of transfected CHO-DG44 cells under serum-free culture conditions. As a result of the presumably greatly reduced enzyme function of these mutants (Asp190G1y, Asp208G1y), only a few cells were s obtained after the selection phase, which were moreover severely impaired in their growth and vitality.
The amino acids at positions 182 and 227 based on the wild-type are non-conserved amino acids which are located outside the three conserved motifs 1 o in the C-terminal region of the aminoglycoside-3'-phosphotransferases. The amino acid at position 91 also belongs to the non-conserved amino acids and is located outside one of the conserved motifs in the N-terminal region of the aminoglycoside-3'-phosphotransferases. By contrast the amino acids at positions 198 and 240 are conserved amino acids in the C-terminal region of is the NPT, but are nevertheless outside the conserved motifs. By contrast, the amino acid at position 261 is a conserved amino acid in the third conserved motif of the C-terminal region (Shaw et al., 1993; Hon et al., 1997; Burk et al., 2001 ).
2 o Compared with the use of wtNPT as selectable marker the cells in the case of the Gfu182G1y, GIu182Asp and Va1198G1y mutant showed a productivity increased by a factor of 1.4 - 2.4, in the case of the Asp227G1y mutant productivity was increased by a factor of 1.6 - 4.1, in the case of the Asp227A1a or Trp91Ala mutant productivity was increased by a factor of 2.2 25 or 4, in the case of the Phe24011e or Asp261Asn mutant productivity was increased by a factor of 5.7 or 7.3 and in the case of the Asp261 Gly or Asp227Va1 mutant it was even increased by a factor of 9.3 or 14.6. To express the multi-chained protein (an antibody), co-transfection was carried out. The two protein chains were each expressed by their own vector, one 3 o vector additionally coding for the NPT gene while the other vector coded for the amplifiable selectable dihydrofolate reductase gene.

The present invention thus relates to a process for enriching for recombinant mammalian cells which express a modified neomycin phosphotransferase gene, characterised in that (i) a pool of mammalian cells is transfected with a gene for a modified neomycin phosphotransferase which has only 1 to 80%, preferably 1 to 60°l°, more preferably 1.5 to 30%, most preferably 1.5 to 26%
of the activity of wild-type neomycin phosphotransferase and/or one of the modifications described herein; (ii) the mammalian cells are cultivated under conditions which allow expression of the modified neomycin phosphotransferase gene; and (iii) the mammalian cells are cultivated in the 1 o presence of at least one selecting agent which acts selectively on the growth of mammalian cells, and gives preference to the growth of those cells which express the neomycin phosphotransferase gene.
Particularly preferred is a corresponding process which uses a modified NPT
s5 gene described in more detail in this application, particularly if the modified NPT gene used codes for a modified NPT which, by comparison with the wild-type gene, codes for alanine at amino acid position 91, for glycine or aspartic acid at amino acid position 182, for glycine at amino acid position 198, for alanine, glycine or valine at amino acid position 227, for glycine or 2 o asparagine at amino acid position 261 or for isoleucine at amino acid position 240. Still more preferred are NPT genes which, by comparison with the wild-type gene, code for valine at amino acid position 227 and /or for glycine and/or asparagine at amino acid position 261. Particularly preferred are those NPT genes which, by comparison with the wild-type gene, code at 2 s amino acid position 240 for an isoleucine or at amino acid position 227 for a valine, while an NPT gene which codes for valine at amino acid position 227 compared with the wild-type gene is particularly preferred. Naturally, the present invention also includes modified NPT genes and the use of modified NPT genes according to the invention which comprise a combination of the 3 o corresponding amino acid exchanges.

The present invention further relates to eukaryotic expression vectors which contain (i) a heterologous gene of interest functionally linked to a heterologous promoter and (ii) a modified neomycin phosphotransferase gene according to the invention which codes for a neomycin s phosphotransferase which has low enzyme activity compared with wild-type neomycin phosphotransferase. By a "low" or "lower" enzyme activity for the purposes of the invention is meant an enzyme activity which corresponds to at most 80%, preferably 1 to 80%, more preferably only 1 to 60% of the enzyme activity of wtNPT. According to one embodiment of the present 1 o invention "lower enzyme activity" denotes an enzyme activity of 1 to 30%, preferably 1.5 to 26% compared with wild-type neomycin phosphotransferase.
A preferred expression vector contains a modified NPT gene which codes for is a modified NPT which has only 1 to 80%, preferably only 1 to 60°l° of the enzyme activity of wtNPT. Also preferred are expression vectors with modified NPT genes which code for mutants having only 1 to 30% of the enzyme activity of wtNPT. Particularly preferred are those expression vectors which contain a modified NPT gene which code for mutants having 2 0 only 1.5 to 26% of the enzyme activity of wtNPT, the activity being determined in the dot assay described in Example 4 and referred to as method 5.
In another embodiment of the invention the expression vectors contain genes 25 of modified NPT which have been modified, compared with wtNPT, at amino acid position Trp91, GIu182, Va1198, Asp227, Phe240 or at position Asp261.
In this context, NPT mutants are preferred which are modified at position Trp91, GIu182, Va1198, Asp227, Phe240 or Asp261 and have only 1 to 80%, preferably only 1 to 60%, more preferably only 1.5 to 30%, and most 3 o preferably only 1.5 to 26% of the enzyme activity of wtNPT. Preferably the amino acids Tryp91, GIu182 or Asp227 may each be replaced by glycine, alanine, valine, leucine, isoleucine, phenylalanine or tyrosine at the corresponding position. Preferably the glutamic acid at position 182 may also be replaced by aspartic acid, asparagine, glutamine or another preferably negatively charged amino acid. Also preferred are modified NPT genes which code for glycine, alanine, leucine, isoleucine, phenylalanine, tyrosine or tryptophan at amino acid position 198 compared with wtNPT. In addition, modified NPT genes are preferred which code for glycine, alanine, valine, isoleucine, tyrosine or tryptophan at amino acid position 240 compared with wtNPT. Also preferred are modified NPT genes which code for glycine, alanine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, asparagine, 1 o glutamine or aspartic acid at amino acid 261 compared with wtNPT. It is particularly preferred to use a mutant wherein the aspartic acid at position 227 is replaced by glycine, alanine, valine, leucine or isoleucine, the aspartic acid at position 261 is replaced by an alanine, valine, leucine, isoleucine or glutamine, particularly by glycine or asparagine.
Particularly preferred are expression vectors which contain modified NPT
genes which code for a GIu182G1y, GIu182Asp, Trp91Ala, Va1198G1y, Asp227A1a, Asp227Va1, Asp227G1y, Asp261 Gly, Asp261 Asn or Phe24011e mutant, which in the case of the GIu182G1y mutant contains the amino acid 2o sequence of SEQ ID N0:4, in the case of the GIu182Asp mutant contains the amino acid sequence of SEQ ID N0:20, in the case of the Trp91Ala mutant contains the amino acid sequence of SEQ ID N0:6, in the case of the Va1198G1y mutant contains the amino acid sequence of SEQ ID N0:8, in the case of the Asp227A1a mutant contains the amino acid sequence of SEQ ID
2 s N0:10, in the case of the Asp227Va1 mutant contains the amino acid sequence of SEQ ID N0:12, in the case of the Asp227G1y mutant contains the amino acid sequence of SEQ ID N0:22, in the case of the Asp261 Gly mutant contains the amino acid sequence of SEQ ID N0:14, in the case of the Asp261Asn mutant contains the amino acid sequence of SEQ ID N0:16 3 o and in the case of the Phe24011e mutant contains the amino acid sequence of SEQ ID N0:18. Most preferred is an expression vector using an Asp227Va1, Asp227G1y, Asp261G1y, Asp261Asn, Phe24011e or Trp91Ala mutant, particularly if it contains the amino acid sequence given in SEQ ID N0:12, SEQ ID N0:22, SEQ ID N0:14, SEQ ID N0:16, SEQ ID N0:18 or SEQ ID
N0:6 or also if it is coded by the nucleic acid sequence given in SEQ ID
N0:11, SEQ ID N0:21, SEQ ID N0:13, SEQ ID N0:15, SEQ ID N0:17 or s SEQ ID N0:5 or contains it.
In addition the present invention provides for the first time modified neomycin phosphotransferase genes and the gene products thereof which compared with wtNPT code for a different amino acid than the wt amino acid at amino 1 o acid position Trp91, Val198 or Phe240. The present invention particularly provides for the first time Trp91, Va1198 or Phe240 mutants which have a reduced enzyme activity compared with wtNPT. The modified NPTs described here and made available within the scope of the invention preferably code for alanine at amino acid position 91, for glycine at position 15 198 and for isoleucine at position 240. Furthermore, the present invention provides for the first time NPT mutants which, compared with wtNPT, code for glycine at position 182, for alanine or valine at position 227 and for glycine at position 261. Both the genes and the gene products (enzymes) are provided for the first time within the scope of the invention. In this context the 2 o present invention provides for the first time modified NPT with the amino acid sequences according to SEQ ID N0:4, SEQ ID N0:6, SEQ ID N0:8, SEQ ID
N0:10, SEQ 1D N0:12, SEQ ID N0:14 and SEQ ID N0:18. Moreover, the present invention provides modified NPT genes with the DNA sequences according to SEQ ID N0:3, SEQ ID N0:5, SEQ ID N0:7, SEQ ID N0:9, SEQ
2 s ID N0:11, SEQ ID N0:13, and SEQ ID N0:17.
Gene of Interest The gene of interest contained in the expression vector according to the 3 o invention comprises a nucleotide sequence of any length which codes for a product of interest. The gene product or "product of interest" is generally a protein, polypeptide, peptide or fragment or derivative thereof. However, it may also be RNA or antisense RNA. The gene of interest may be present in its full length, in shortened form, as a fusion gene or as a labelled gene. It may be genomic DNA or preferably cDNA or corresponding fragments of fusions. The gene of interest may be the native gene sequence, or it may be mutated or otherwise modified. Such modifications include codon optimisations for adapting to a particular host cell and humanisation. The gene of interest may, for example, code for a secreted, cytoplasmic, nuclear-located, membrane-bound or cell surface-bound polypeptide.
1 o The term "nucleotide sequence" or "nucleic acid sequence" indicates an oligonucleotide, nucleotides, polynucleotides and fragments thereof as well as DNA or RNA of genomic or synthetic origin which occur as single or double strands and can represent the coding or non-coding strand of a gene.
Nucleic acid sequences may be modified using standard techniques such as 15 site-specific mutagenesis or PCR-mediated mutagenesis (e.g. described in Sambrook et al., 1989 or Ausubel et al., 1994).
By "coding" is meant the property or capacity of a specific sequence of nucleotides in a nucleic acid, for example a gene in a chromosome or an 2 o mRNA, to act as a matrix for the synthesis of other polymers and macromolecules such as for example rRNA, tRNA, mRNA, other RNA
molecules, cDNA or polypeptides in a biological process. Accordingly, a gene codes for a protein if the desired protein is produced in a cell or another biological system by transcription and subsequent translation of the mRNA.
2 s Both the coding strand whose nucleotide sequence is identical to the mRNA
sequence and is normally also given in sequence databanks, e.g. EMBL or GenBank, and also the non-coding strand of a gene or cDNA which acts as the matrix for transcription may be referred to as coding for a product or protein. A nucleic acid which codes for a protein also includes nucleic acids 3 o which have a different order of nucleotide sequence on the basis of the degenerate genetic code but result in the same amino acid sequence of the protein. Nucleic acid sequences which code for proteins may also contain introns.
The term cDNA denotes deoxyribonucleic acids which are prepared by reverse transcription and synthesis of the second DNA strand from a mRNA
or other RNA produced from a gene. If the cDNA is present as a double stranded DNA molecule it contains both a coding and a non-coding strand.
The term intron denotes non-coding nucleotide sequences of any length.
to They occur naturally in numerous eukaryotic genes and are eliminated from a previously transcribed mRNA precursor by a process known as splicing. This requires precise excision of the intron at the 5' and 3' ends and correct joining of the resulting mRNA ends so as to produce a mature processed mRNA with the correct reading frame for successful protein synthesis. Many of the splice donor and splice acceptor sites involved in this splicing process, i.e. the sequences located directly at the exon-intron or intron-exon intertaces, have been characterised by now. For an overview see Ohshima et al., 1987.
Protein/Product of Interest Proteins/polypeptides with a biopharmaceutical significance include for example antibodies, enzymes, cytokines, lymphokines, adhesion molecules, receptors and the derivatives or fragments thereof, but are not restricted thereto. Generally, all polypeptides which act as agonists or antagonists and/or have therapeutic or diagnostic applications are of value.
The term "polypeptides" is used for amino acid sequences or proteins and refers to polymers of amino acids of any length. This term also includes proteins which have been modified post-translationally by reactions such as 3 o glycosylation, phosphorylation, acetylation or protein processing. The structure of the polypeptide may be modified, for example, by substitutions, deletions or insertions of amino acids and fusion with other proteins while retaining its biological activity. The term "polypeptides" thus also includes, for example, fusion proteins consisting of an immunoglobulin component, e.g.
the Fc component, and a growth factor, e.g. an interleukin.
Examples of therapeutic proteins are insulin, insulin-like growth factor, human growth hormone (hGH) and other growth factors, tissue plasminogen activator (tPA), erythropoietin (EPO), cytokines, e.g. interleukines (IL) such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18 interferon (IFN)-alpha, -beta, -gamma, -omega to or -tau, tumour necrosis factor (TNF) such as TNF-alpha, beta or gamma, TRAIL, G-CSF, GM-CSF, M-CSF, MCP-1 and VEGF. Other examples are monoclonal, polyclonal, multispecific and single chain antibodies and fragments thereof such as for example Fab, Fab', F(ab')2, Fc and Fc' fragments, light (L) and heavy (H) immunoglobulin chains and the constant, variable or hypervariable regions thereof as well as Fv and Fd fragments (Chamov et al., 1999). The antibodies may be of human or non-human origin. Humanised and chimeric antibodies are also possible.
Fab fragments (fragment antigen binding = Fab) consist of the variable 2 o regions of both chains which are held together by the adjacent constant regions. They may be produced for example from conventional antibodies by treating with a protease such as papain or by DNA cloning. Other antibody fragments are F(ab')2 fragments which can be produced by proteolytic digestion with pepsin.

By gene cloning it is also possible to prepare shortened antibody fragments which consist only of the variable regions of the heavy (VH) and light chain (VL). These are known as Fv fragments (fragment variable = fragment of the variable part). As covalent binding via the cystein groups of the constant chains is not possible in these Fv fragments, they are often stabilised by some other method. For this purpose the variable region of the heavy and light chains are often joined together by means of a short peptide fragment of about 10 to 30 amino acids, preferably 15 amino acids. This produces a single polypeptide chain in which VH and VL are joined together by a peptide linker. Such antibody fragments are also referred to as single chain Fv fragments (scFv). Examples of scFv antibodies are known and described, cf.
s for example Huston et al., 1988.
In past years various strategies have been developed for producing multimeric scFv derivatives. The intention is to produce recombinant antibodies with improved pharmacokinetic properties and increased binding to avidity. In order to achieve the multimerisation of the scFv fragments they are produced as fusion proteins with multimerisation domains. The multimerisation domains may be, for example, the CH3 region of an IgG or helix structures ("coiled coil structures") such as the Leucine Zipper domains.
In other strategies the interactions between the VH and VL regions of the 15 scFv fragment are used for multimerisation (e.g. dia, tri- and pentabodies).
The term diabody is used in the art to denote a bivalent homodimeric scFv derivative. Shortening the peptide linker in the scFv molecule to 5 to 10 amino acids results in the formation of homodimers by superimposing VH/VL
2 o chains. The diabodies may additionally be stabilised by inserted disulphite bridges. Examples of diabodies can be found in the literature, e.g. in Perisic et al., 1994.
The term minibody is used in the art to denote a bivalent homodimeric scFv 2 s derivative. It consists of a fusion protein which contains the CH3 region of an immunoglobulin, preferably IgG, most preferably IgG1, as dimerisation region. This connects the scFv fragments by means of a hinge region, also of IgG, and a linker region. Examples of such minibodies are described by Hu et al., 1996.

The term triabody is used in the art to denote a trivalent homotrimeric scFv derivative (Kortt et al., 1997). The direct fusion of VH VL without the use of a linker sequence leads to the formation of trimers.
s The fragments known in the art as mini antibodies which have a b-i, tri- or tetravalent structure are also derivatives of scFv fragments. The multimerisation is achieved by means of di, tri- or tetrameric coiled coil structures (Pack et al., 1993 and 1995; Lovejoy et al., 1993).
1 o Gene which codes for a fluorescent protein In another embodiment the expression vector according to the invention contains a gene coding for a fluorescent protein, preferably functionally linked to the gene of interest. Preferably, both genes are transcribed under the 15 control of a single heterologous promoter so that the protein/ product of interest and the fluorescent protein are coded by a bicistronic mRNA. This makes it possible to identify cells which produce the protein/product of interest in large amounts, by means of the expression rate of the fluorescent protein.
The fluorescent protein may be, for example, a green, bluish-green, blue, yellow or other coloured fluorescent protein. One particular example is green fluorescent protein (GFP) obtained from Aequorea victoria or Renilla reniformis and mutants developed from them; cf. for example Bennet et al., 2 s 1998; Chalfie et al., 1994; WO 01 /04306 and the literature cited therein.
Other fluorescent proteins and genes coding for them are described in WO
00/34318, WO 00/34326, WO 00/34526 and WO 01/27150 which are incorporated herein by reference. These fluorescent proteins are 3 o fluorophores of non-bioluminescent organisms of the species Anthozoa, for example Anemonia majano, Clavularia sp., Zoanthus sp. I, Zoanthus sp. II, Discosoma striafa, Discosoma sp. "red'; Discosoma sp. "green'; Discosoma sp. "Magenta'; Anemonia sulcafa.
The fluorescent proteins used according to the invention contain in addition to s the wild-type proteins natural or genetically engineered mutants and variants, fragments, derivatives or variants thereof which have for example been fused with other proteins or peptides. The mutations used may for example alter the excitation or emission spectrum, the formation of chromophores, the extinction coefficient or the stability of the protein. Moreover, the expression to in mammalian cells or other species can be improved by codon optimisation.
According to the invention the fluorescent protein may also be used in fusion with a selectable marker, preferably an amplifiable selectable marker such as dihydrofolate reductase (DHFR).
15 The fluorescence emitted by the fluorescent proteins makes it possible to detect the proteins, e.g. by throughflow cytometry with a fluorescence-activated cell sorter (FACS) or by fluorescence microscopy.

Other reaulatory elements The expression vector contains at least one heterologous promoter which allows expression of the gene of interest and preferably also of the fluorescent protein.
The term promoter denotes a polynucleotide sequence which allows and controls the transcription of the genes or sequences functionally connected therewith. A promoter contains recognition sequences for binding RNA
to polymerase and the initiation site for transcription (transcription initiation site).
In order to express a desired sequence in a certain cell type or a host cell a suitable functional promoter must be chosen. The skilled man will be familiar with a variety of promoters from various sources, including constitutive, inducible and repressible promoters. They are deposited in databanks such as GenBank, for example, and may be obtained as separate elements or elements cloned within polynucleotide sequences from commercial or individual sources. In inducible promoters the activity of the promoter may be reduced or increased in response to a signal. One example of an inducible promoter is the tetracycline (tet) promoter. This contains tetracycline 2 0 operator sequences (tet0) which can be induced by a tetracycline-regulated transactivator protein (tTA). In the presence of tetracycline the binding of tTA
to tet0 is inhibited. Examples of other inducible promoters are the jun, fos, metallothionein and heat shock promoter (see also Sambrook et al., 1989;
Gossen et al., 1994).
Of the promoters which are particularly suitable for high expression in eukaryotes, there are for example the ubiquitin/S27a promoter of the hamster (VllO 97/15664), SV 40 early promoter, adenovirus major late promoter, mouse metallothionein-I promoter, the long terminal repeat region of Rous 3 o Sarcoma Virus, the early promoter of human Cytomegalovirus. Examples of other heterologous mammalian promoters are the actin, immunoglobulin or heat shock promoter(s).

A corresponding heterologous promoter can be functionally connected to other regulatory sequences in order to increase/regulate the transcription activity in an expression cassette.
For example, the promoter may be functionally linked to enhancer sequences in order to increase the transcriptional activity. For this, one or more enhancers and/or several copies of an enhancer sequence may be used, e.g.
a CMV or SV40 enhancer. Accordingly, an expression vector according to to the invention, in another embodiment, contains one or more enhancers/
enhancer sequences, preferably a CMV or SV40 enhancer.
The term enhancer denotes a polynucleotide sequence which in the cis location acts on the activity of a promoter and thus stimulates the transcription of a gene functionally connected to this promoter. Unlike promoters the effect of enhancers is independent of position and orientation and they can therefore be positioned in front of or behind a transcription unit, within an intron or even within the coding region. The enhancer may be located both in the immediate vicinity of the transcription unit and at a 2 o considerable distance from the promoter. It is also possible to have a physical and functional overlap with the promoter. The skilled man will be aware of a number of enhancers from various sources (and deposited in databanks such as GenBank, e.g. SV40 enhancers, CMV enhancers, polyoma enhancers, adenovirus enhancers) which are available as independent elements or elements cloned within polynucleotide sequences (e.g. deposited at the ATCC or from commercial and individual sources). A
number of promoter sequences also contain enhancer sequences such as the frequently used CMV promoter. The human CMV enhancer is one of the strongest enhancers identified hitherto. One example of an inducible 3 o enhancer is the metallothionein enhancer, which can be stimulated by glucocorticoids or heavy metals.

Another possible modification is, for example, the introduction of multiple Sp1 binding sites. The promoter sequences may also be combined with regulatory sequences which allow control/regulation of the transcription activity. Thus, the promoter can be made repressible/ inducible. This can be done for example by linking to sequences which are binding sites for up- or down-regulating transcription factors. The above mentioned transcription factor Sp1, for example, has a positive effect on the transcription activity.
Another example is the binding site for the activator protein AP1, which may act both positively and negatively on transcription. The activity of AP1 can be ~.o controlled by all kinds of factors such as, for example, growth factors, cytokines and serum (Faisst et al., 1992 and references therein). The transcription efficiency can also be increased by changing the promoter sequence by the mutation (substitution, insertion or deletion) of one, two, three or more bases and then determining, in a reporter gene assay, whether this has increased the promoter activity.
Basically, the additional regulatory elements include heterologous promoters, enhancers, termination and polyadenylation signals and other expression control elements. Both inducible and constitutively regulatory sequences are 2 o known for the various cell types.
"Transcription-regulatory elements" generally comprise a promoter upstream of the gene sequence to be expressed, transcription initiation and termination sites and a polyadenylation signal.
The term "transcription initiation site" refers to a nucleic acid in the construct which corresponds to the first nucleic acid which is incorporated in the primary transcript, i.e. the mRNA precursor. The transcription initiation site may overlap with the promoter sequences.
The term "transcription termination site" refers to a nucleotide sequence which is normally at the 3' end of the gene of interest or of the gene section which is to be transcribed, and which brings about the termination of transcription by RNA polymerase.
The "polyadenylation signal" is a signal sequence which causes cleavage at a specific site at the 3' end of the eukaryotic mRNA and post-transcriptional incorporation of a sequence of about 100-200 adenine nucleotides (polyA tail) at the cleaved 3' end. The polyadenylation signal comprises the sequence AATAAA about 10-30 nucleotides upstream of the cleavage site and a sequence located downstream. Various polyadenylation elements are known 1 o such as tk polyA, SV40 late and early polyA or BGH polyA (described for example in US 5,122,458).
In a preferred embodiment of the present invention each transcription unit has a promoter or a promoter/enhancer element, a gene of interest andlor a marker gene as well as a transcription termination element. In another preferred embodiment the transcription unit contains two further translation regulatory units.
"Translation regulatory elements" comprise a translation initiation site (AUG), 2 o a stop codon and a polyA signal for each polypeptide to be expressed. For optimum expression it may be advisable to remove, add or change 5'- and/or 3'-untranslated regions of the nucleic acid sequence which is to be expressed, in order to eliminate any potentially unsuitable additional translation initiation codons or other sequences which might affect expression at the transcription or expression level. In order to promote expression, ribosomal consensus binding sites may alternatively be inserted immediately upstream of the start codon. In order to produce a secreted polypeptide the gene of interest usually contains a signal sequence which codes for a signal precursor peptide which transports the synthesised polypeptide to and 3 o through the ER membrane. The signal sequence is often but not always located at the amino terminus of the secreted protein and is cleaved by signal peptidases after the protein has been filtered through the ER membrane.

The gene sequence will usually but not necessarily contain its own signal sequence. If the native signal sequence is not present a heterologous signal sequence may be introduced in known manner. Numerous signal sequences of this kind are known to the skilled man and deposited in sequence databanks such as GenBank and EMBL.
One important regulatory element according to the invention is the internal ribosomal entry site (IRES). The IRES element comprises a sequence which functionally activates the translation initiation independently of a 5'-terminal to methylguanosinium cap (CAP structure) and the upstream gene and in an animal cell allows the translation of two cistrons (open reading frames) from a single transcript. The IRES element provides an independent ribosomal entry site for the translation of the open reading frame located immediately downstream. In contrast to bacterial mRNA which may be multicistronic, i.e.
15 it may code for numerous different polypeptides or products which are translated one after the other by the mRNA, the majority of mRNAs from animal cells are monocistronic and code for only one protein or product. In the case of a multicistronic transcript in a eukaryotic cell the translation would be initiated from the translation initiation site which was closest upstream and 2 o would be stopped by the first stop codon, after which the transcript would be released from the ribosome. Thus, only the first polypeptide or product coded by the mRNA would be produced during translation. By contrast, a multicistronic transcript with an IRES element which is functionally linked to the second or subsequent open reading frame in the transcript allows 2 s subsequent translation of the open reading frame located downstream thereof, so that two or more polypeptides or products coded by the same transcript are produced in the eukaryotic cell.
The IRES element may be of various lengths and various origins and may 3 0 originate, for example, from the encephalomyocarditis virus (EMCV) or other Picorna viruses. Various IRES sequences and their use in the construction of vectors are described in the literature, cf. for example Pelletier et al., 1988;

Jang et al., 1989; Davies et al., 1992; Adam et al., 1991; Morgan et al., 1992;
Sugimoto et al., 1994; Ramesh et al., 1996; Mosser et al., 1997.
The gene sequence located downstream is functionally linked to the 3' end of the IRES element, i.e. the spacing is selected so that the expression of the gene is unaffected or only marginally affected or has sufficient expression for the intended purpose. The optimum permissible distance between the IRES
element and the start colon of the gene located downstream thereof for sufficient expression can be determined by simple experiments by varying the 1 o spacing and determining the expression rate as a function of the spacing using reporter gene assays.
By the measures described it is possible to obtain an optimum expression cassette which is of great value for the expression of heterologous gene products. An expression cassette obtained by means of one or more such measures is therefore a further subject of the invention.
Hamster-Ubiauitin/S27a Promoter 2 o In another embodiment the expression vector according to the invention contains the ubiquitin/S27a promoter of the hamster, preferably functionally linked to the gene of interest and even more preferably functionally linked to the gene of interest and the gene which codes for a fluorescent protein.
The ubiquitin/S27a promoter of the hamster is a powerful homologous promoter which is described in WO 97/15664. Such a promoter preferably has at least one of the following features: GC-rich sequence area, Sp1 binding site, polypyrimidine element, absence of a TATA box. Particularly preferred is a promoter which has an Sp1 binding site but no TATA box. Also 3 o preferred is a promoter which is constitutively activated and in particular is equally active under serum-containing, low-serum and serum-free cell culture conditions. In another embodiment it is an inducible promoter, particularly a promoter which is activated by the removal of serum.
A particularly advantageous embodiment is a promoter with a nucleotide sequence as contained in Fig. 5 of WO 97/15664. Particularly preferred are promoter sequences which contain the sequence from position -161 to -45 of Fig. 5.
The promoters used in the examples of the present patent specification each 1 o contain a DNA molecule with the sequence from position 1923 to 2406 of SEQ ID N0:55 of the attached sequence listing. This sequence corresponds to the fragment -372 to +111 from Fig. 5 of WO 97/15664 and represents the preferred promoter, i.e a preferred promoter should incorporate this sequence region. Another suitable promoter fragment contains the sequence from position 2134 to 2406 (corresponding to -161 to +111 in Fig. 5 of WO
97/15664). A promoter which contains only the sequence from position 2251 to 2406 is no longer functional (corresponds to position -45 to +111 in Fig. 5 of WO 9/15664). It is possible to extend the promoter sequence in the 5' direction starting from position 2134.
It is also possible to use functional subfragments of the complete hamster ubiquitin/S27a promoter sequence as well as functional mutants/variants of the complete sequence of subfragments thereof which have been modified, for example, by substitution, insertion or deletion. Corresponding 2 5 subfragments, mutants or variants are hereinafter also referred to as "modified promoters".
A modified promoter, optionally combined with other regulatory elements, preferably has a transcription activity which corresponds to that of the 3 o promoter fragment from position 1923 to 2406 of the nucleotide sequence given in SEQ ID N0:55 (-372 to +111 from Fig. 5 of WO 97/15664). A
modified promoter proves to be useful for the purposes of the invention if it has a transcription activity which has at least 50%, preferably at least 80%, more preferably at least 90% and most preferably at least 100% of the activity of the 1923 to 2406 fragment (-372 to +111 fragment) in a comparative reporter gene assay. Particularly preferred are modified promoters which s have a minimum sequence homology to the wild-type sequence SEQ ID
N0:55 of the hamster ubiquitin/ S27a promoter of at least 80%, preferably at least 85%, preferably at least 90%, more preferably at least 95% and most preferably at least 97% and have a corresponding promoter activity in a comparative reporter gene assay.
to In a corresponding comparative reporter gene assay the promoter fragments to be tested including the reference sequence are cloned in front of a promoterfess reporter gene which codes, for example for luciferase, secreted alkaline phosphotase or green fluorescent protein (GFP). These constructs 15 (promoter sequence + reporter gene) are subsequently introduced into the test cells, e.g. CHO-DG44, by transfection and the induction of the reporter gene expression by the promoter fragment in question is determined by measuring the protein content of the reporter gene. A corresponding test is found for example in Ausubel et al., Current Protocols in Molecular Biology, 2 0 1994, updated.
The promoter sequence of the hamster ubiquitin/S27a promoter and the modified promoters, which may also include, for example, the 5' untranslated region or selected fragments thereof, and the coding region as well as the 3'-2 s untranslated region of the ubiquitin/S27a gene or selected fragments thereof, may be obtained by a skilled man with a knowledge of the sequence described in WO 97/15664 using various standard methods as described for example in Sambrook et al., 1989; Ausubel et al., 1994. Starting from the sequence described in WO 97/15664 a suitable fragment may be selected, 3 o for example, and an oligonucleotide probe containing the sequence of this fraction may be chemically synthesised. A probe of this kind may be used for example to clone the ubiquitinlS27a gene or the 5' untranslated region or other fragments thereof, for example by hybridisation from a library of the hamster genome. Using the reporter gene assay described above the skilled man is in a position to identify promoter-active fragments without any great effort and use them for the purposes of the present invention. The 5' untranslated region or special fragments thereof can easily be obtained by PCR amplification with corresponding primers from genomic DNA or a genomic library. Fragments of the 5' untranslated region may also be obtained by limited exonuclease III digestion from larger DNA fragments.
Such DNA molecules may also be chemically synthesised or produced from 1 o chemically synthesised fragments by ligation.
Deletion, insertion and substitution mutants may be produced by "site-specific mutagenesis" and/or "PCR-based mutagenesis techniques". Corresponding methods are mentioned for example in Lottspeich and Zorbas 1998 Chapter 36.1 with further references.
By cross-hybridisation with probes from the 5' untranslated region of the hamster ubiquitin/S27a gene or from the S27a part of the hamster ubiquitin S27a gene or the 3'-untranslated region it is also possible to identify and 2 o isolate suitable promoter sequences from corresponding homologous genes of other, preferably mammalian species. Suitable techniques are described by way of example in Lottspeich and Zorbas 1998 Chapter 23. Genes are "homologous" for the purposes of the invention if their nucleotide sequence exhibits at least 70%, preferably at least 80%, preferably at least 90%, more preferably at least 95% and most preferably at least 97% conformity to the nucleotide sequence of the gene with which it is homologous.
Using the measures described above it is possible to obtain an optimised expression cassette which is highly valuable for the expression of 3 o heterologous gene products. An expression cassette obtained by one or more such measures is therefore a further object of the invention.

Preparation of expression vectors according to the invention The expression vector according to the invention may theoretically be prepared by conventional methods known in the art, as described by s Sambrook et al. (1989), for example. Sambrook also describes the functional components of a vector, e.g. suitable promoters (in addition to the hamster ubiquitinlS27a promoter), enhancers, termination and polyadenylation signals, antibiotic resistance genes, selectable markers, replication starting points and splicing signals. Conventional cloning vectors may be used to 1 o produce them, e.g. plasmids, bacteriophages, phagemids, cosmids or viral vectors such as baculovirus, retroviruses, adenoviruses, adeno-associated viruses and herpes simplex virus, as well as artificial chromosomes/mini chromosomes. The eukaryotic expression vectors typically also contain prokaryotic sequences such as, for example, replication origin and antibiotic 15 resistance genes which allow replication and selection of the vector in bacteria. A number of eukaryotic expression vectors which contain multiple cloning sites for the introduction of a polynucleotide sequence are known and some may be obtained commercially from various companies such as Stratagene, La Jolla, CA, USA; Invitrogen, Carlsbad, CA, USA; Promega, 2 o Madison, WI, USA or BD Biosciences Clontech, Palo Alto, CA, USA.
The heterologous promoter, the gene of interest and the modified neomycin phosphotransferase gene and optionally the gene coding for a fluorescent protein, additional regulatory elements such as the internal ribosomal entry 2s site (IRES), enhancers or a polyadenylation signal are introduced into the expression vector in a manner familiar to those skilled in the art. An expression vector according to the invention contains, at the minimum, a heterologous promoter, the gene of interest and a modified neomycin phosphotransferase gene. Preferably, the expression vector also contains a 3 o gene coding for a fluorescent protein. It is particularly preferred according to the invention to use a ubiquitin/S27a promoter as heterologous promoter.
Particularly preferred is an expression vector in which the heterologous promoter, preferably a ubiquitin/S27a promoter, the gene of interest and the gene which codes for a fluorescent protein are functionally linked together or are functionally linked and the neomycin phosphotransferase gene is located in the same or in a separate transcription unit.
Within the scope of the present description the term "functional linking" or "functionally linked" refers to two or more nucleic acid sequences or partial sequences which are positioned so that they can perform their intended function. For example, a promoter/enhancer is functionally linked to a coding 1 o gene sequence if it is able to control or modulate the transcription of the linked gene sequence in the cis position. Generally, but not necessarily, functionally linked DNA sequences are close together and, if two coding gene sequences are linked or in the case of a secretion signal sequence, in the same reading frame. Although a functionally finked promoter is generally located upstream of the coding gene sequence it does not necessarily have to be close to it. Enhancers need not be close by either, provided that they assist the transcription of the gene sequence. For this purpose they may be both upstream and downstream of the gene sequence, possibly at some distance from it. A polyadenylation site is functionally linked to a gene 2 o sequence if it is positioned at the 3' end of the gene sequence in such a way that the transcription progresses via the coding sequence to the polyadenylation signal. Linking may take place according to conventional recombinant methods, e.g. by the PCR technique, by ligation at suitable restriction cutting sites or by splicing. If no suitable restriction cutting sites 2 5 are available synthetic oligonucleotide linkers or adaptors may be used in a manner known per se. According to the invention the functional linking preferably does not take place via intron sequences.
In one of the embodiments described, the heterologous promoter, preferably 3o a ubiquitin/S27a promoter, the gene of interest and the gene coding for a fluorescent protein are functionally linked together. This means for example that both the gene of interest and the gene coding for a fluorescent protein are expressed starting from the same heterologous promoter.
In a particularly preferred embodiment the functional linking takes place via an IRES element, so that a bicistronic mRNA is synthesised from both genes.
The expression vector according to the invention may additionally contain enhancer elements which act functionally on one or more promoters.
Particularly preferred is an expression vector in which the heterologous promoter, preferably the ubiquitin/S27a promoter or a modified form thereof, 1 o is linked to an enhancer element, e.g. an SV40 enhancer or a CMV enhancer element.
Fundamentally, the expression of the genes within an expression vector may take place starting from one or more transcription units. The term transcription unit is defined as a region which contains one or more genes to be transcribed. The genes within a transcription unit are functionally linked to one another in such a way that all the genes within such a unit are under the transcriptional control of the same promoter or promoter/ enhancer. As a result of this transcriptional linking of genes, more than one protein or product 2 o can be transcribed from a transcription unit and thus expressed. Each transcription unit contains the regulatory elements which are necessary for the transcription and translation of the gene sequences contained therein.
Each transcription unit may contain the same or different regulatory elements.
IRES elements or introns may be used for the functional linking of the genes 2 5 within a transcription unit.
The expression vector may contain a single transcription unit for expressing the gene of interest, the modified NPT gene and optionally the gene which codes for the fluorescent protein. Alternatively, these genes may also be 3 o arranged in two or more transcription units. Various combinations of the genes within a transcription unit are possible. In another embodiment of the present invention more than one expression vector consisting of one, two or more transcription units may be inserted in a host cell by cotransfection or in successive transfections in any desired order. Any combination of regulatory elements and genes on each vector can be selected provided that adequate expression of the transcription units is ensured. If necessary, other regulatory elements and genes, e.g. additional genes of interest or selectable markers, may be positioned on the expression vectors.
Accordingly, an expression vector according to the invention containing a gene of interest and a gene which codes for a modified neomycin to phosphotransferase may contain both genes in one or in two separate transcription units. Each transcription unit can transcribe and express one or more gene products. If both genes are contained in one transcription unit they are under the control of the same promoter or promoter/ enhancer, while preferably an IRES element is used to ensure the functional linking of all the components. If the gene which codes for modified neomycin phosphotransferase and the gene of interest are contained in two separate transcription units, they may be under the control of the same or different promoterslenhancers. However, preferably, a weaker heterologous promoter, e.g. SV40 early promoter, is used for the modified NPT gene and 2 o preferably no enhancer is used. Expression vectors with two separate transcription units are preferred within the scope of the invention. One (bicistronic) transcription unit contains the gene of interest and optionally a gene coding for a fluorescent protein, while the other transcription unit contains the modified NPT gene. Preferably, each transcription unit is limited 2 5 at the 3' end by a sequence which codes for a polyA signal, preferably BGH
polyA or SV40 polyA.
Also preferred according to the invention are those expression vectors which instead of the gene of interest have only a multiple cloning site which allows 3 o the cloning of the gene of interest via recognition sequences for restriction endonucleases. Numerous recognition sequences for all kinds of restriction endonucleases as well as the associated restriction endonucleases are known from the prior art. Preferably, sequences are used which consist of at least six nucleotides as recognition sequence. A list of suitable recognition sequences can be found for example in Sambrook et al., 1989.
Host Cells For transfection with the expression vector according to the invention eukaryotic host cells are used, preferably mammalian cells and more particularly rodent cells such as mouse, rat and hamster cell lines. The 1 o successful transfection of the corresponding cells with an expression vector according to the invention results in transformed, genetically modified, recombinant or transgenic cells, which are also the subject of the present invention.
Preferred host cells for the purposes of the invention are hamster cells such as BHK21, BHK TK- CHO, CHO-K1, CHO-DUKX, CHO-DUKX B1 and CHO-DG44 cells or derivatives/descendants of these cell lines. Particularly preferred are CHO-DG44, CHO-DUKX, CHO-K1 and BHK21 cells, particularly CHO-DG44 and CHO-DUKX cells. Also suitable are myeloma 2 o cells from the mouse, preferably NSO and Sp2/0 cells and derivatives/descendants of these cell lines.
Examples of hamster and mouse cells which can be used according to the invention are given in Table 1 that follows. However, derivatives and descendants of these cells, other mammalian cells including but not restricted to cell lines of humans, mice, rats, monkeys, rodents, or eukaryotic cells, including but not restricted to yeast, insect and plant cells, may also be used as host cells for the production of biopharmaceutical proteins.
3 o Table 1: Hamster and Mouse Production Cell Lines Cell line Accession Number NSO ECASS No. 85110503 Sp2/0-Ag14 ATCC CRL-1581 BHK TK- ECACC No. 85011423 HaK ATCC CCL-15 2254-62.2 ATCC CRL-8544 (BHK-21-derivative) CHO ECACC No. 8505302 (= CHO duk- CHO/dhf~ ) CHO-DG44 Urlaub et al;
Cell 32[2], 405-412, 1983 CHO Pro-5 ATCC CRL-1781 CHL ECACC No. 87111906 The transfection of the eukaryotic host cells with a polynucleotide or one of the expression vectors according to the invention is carried out by conventional methods (Sambrook et al., 1989; Ausubel et al., 1994). Suitable methods of transfection include for example lyposome-mediated transfection, calcium phosphate co precipitation, electroporation, polycation- (e.g. DEAE
dextran)-mediated transfection, protoplast fusion, microinjection and viral infections. According to the invention stable transfection is preferably carried out in which the constructs are either integrated into the genome of the host to cell or an artificial chromosome/minichromosome, or are episomally contained in stable manner in the host cell. The transfection method which gives the optimum transfection frequency and expression of the heterologous gene in the host cell in question is preferred. By definition, every sequence or every gene inserted in a host cell is referred to as a "heterologous sequence" or "heterologous gene" in relation to the host cell. This applies even if the sequence to be introduced or the gene to be introduced is identical to an endogenous sequence or an endogenous gene of the host cell. For example, a hamster actin gene introduced into a hamster host cell is by definition a heterologous gene.
According to the invention, recombinant mammalian cells, preferably rodent to cells, most preferably hamster cells such as CHO or BHK cells which have been transfected with one of the expression vectors according to the invention described herein are preferred.
In the recombinant production of heteromeric proteins such as e.g.
monoclonal antibodies (mAb), the transfection of suitable host cells can theoretically be carried out by two different methods. mAb's of this kind are composed of a number of subunits, the heavy and light chains. Genes coding for these subunits may be accommodated in independent or multicistronic transcription units on a single plasmid with which the host cell is then 2 o transfected. This is intended to secure the stoichiometric representation of the genes after integration into the genome of the host cell. However, in the case of independent transcriptional units it must hereby be ensured that the mRNAs which encode the different proteins display the same stability and transcriptional and translational efficiency. In the second case, the expression of the genes take place within a multicistronic transcription unit by means of a single promoter and only one transcript is formed. By using IRES elements, a highly efficient internal translation initiation of the genes is obtained in the second and subsequent cistrons. However, the expression rates for these cistrons are lower than that of the first cistron, the translation initiation of 3 o which, by means of a so-called "cap"-dependent pre-initiation complex, is substantially more efficient than IRES-dependent translation initiation. In order to achieve a truly equimolar expression of the cistrons, additional inter-cistronic elements may be introduced, for example, which ensure uniform expression rates in conjunction with the IRES elements (WO 94/05785).
Another possible way of simultaneously producing a number of heterologous proteins, which is preferred according to the invention, is cotransfectian, in which the genes are separately integrated in different expression vectors.
This has the advantage that certain proportions of genes and gene products with one another can be adjusted, thereby balancing out any differences in the mRNA stability and in the efficiency of transcription and translation. In 1 o addition, the expression vectors are more stable because of their small size and are easier to handle both during cloning and during transfection.
In one particular embodiment of the invention, therefore, the host cells are additionally transfected, preferably cotransfected, with one or more vectors having genes which code for one or more other proteins of interest. The other vector or vectors used for the cotransfection code, for example, for the other protein or proteins of interest under the control of the same promoter/enhancer combination and for at least one other selectable marker, e.g. dihydrofolate reductase.
According to the invention the host cells are preferably established, adapted and cultivated under serum-free conditions, optionally in media which are free from animal proteins/peptides. Examples of commercially obtainable media include Ham's F12 (Sigma, Deisenhofen, DE), RPMI-1640 (Sigma), 2s Dulbecco's Modified Eagle's Medium (DMEM; Sigma), Minimal Essential Medium (MEM; Sigma), Iscove's Modified Dulbecco's Medium (IMDM;
Sigma), CD-CHO (Invitrogen, Carlsbad, CA, USA), CHO-S-SFMII
(Invitrogen), serum-free CHO-Medium (Sigma) and protein-free CHO-Medium (Sigma). Each of these media may optionally be supplemented with various 3 o compounds, e.g. hormones and/or other growth factors (e.g. insulin, transferrin, epidermal growth factor, insulin-like growth factor), salts (e.g.
sodium chloride, calcium, magnesium, phosphate), buffers (e.g. HEPES), nucleosides (e.g. adenosine, thymidine), glutamine, glucose or other equivalent nutrients, antibiotics and/or trace elements. Although serum-free media are preferred according to the invention, the host cells may also be cultivated and protein subsequently produced using media which have been s mixed with a suitable amount of serum. In order to select genetically modified cells which express one or more selectable marker genes, one or more selecting agents are added to the medium.
The term "selecting agent" refers to a substance which affects the growth or 1 o survival of host cells with a deficiency for the selectable marker gene in question. Within the scope of the present invention, geneticin (G418) is preferably used as the medium additive for the selection of heterologous host cells which carry a modified neomycin phosphotransferase gene. Preferably, 6418 concentrations of between 100 and 800 :g/ml of medium are used, is most preferably 300 to 400 :g/ml of medium. If the host cells are to be transfected with a number of expression vectors, e.g. if several genes of interest are to be separately introduced into the host cell, they generally have different selectable marker genes.
2 o A selectable marker gene is a gene which allows the specific selection of cells which contain this gene by the addition of a corresponding selecting agent to the cultivation medium. As an illustration, an antibiotic resistance gene may be used as a positive selectable marker. Only cells which have been transformed with this gene are able to grow in the presence of the 25 corresponding antibiotic and are thus selected. Untransformed cells, on the other hand, are unable to grow or survive under these selection conditions.
There are positive, negative and bifunctional selectable markers. Positive selectable markers permit the selection and hence enrichment of transformed cells by conferring resistance to the selecting agent or by compensating for a 3 o metabolic or catabolic defect in the host cell. By contrast, cells which have received the gene for the selectable marker can be selectively eliminated by negative selectable markers. An example of this is the thymidine kinase gene of the Herpes Simplex virus, the expression of which in cells with the simultaneous addition of acyclovir or gancyclovir leads to the elimination thereof. The selectable markers used in this invention, including the amplifiable selectable markers, include genetically modified mutants and variants, fragments, functional equivalence, derivatives, homologues and fusions with other proteins or peptides, provided that the selectable marker retains its selective qualities. Such derivatives display considerable homology in the amino acid sequence in the regions or domains which are deemed to be selective. The literature describes a large number of 1 o selectable marker genes including bifunctional (positive/negative) markers (see for example WO 92/08796 and WO 94/28143). Examples of selectable markers which are usually used in eukaryotic cells include the genes for aminoglycoside phosphotransferase (APH), hygromycine phosphostransferase (HYG), dihydrofolate reductase (DHFR), thymidine 1s kinase (TK), glutamine synthetase, asparagin synthetase and genes which confer resistance to neomycin (G418), puromycin, histidinol D, belomycin, phleomycin and zeocin.
It is also possible to select transformed cells by fluorescence-activated cell 2 o sorting (FACS). For this, bacterial 3-galactosidase, cell surface markers or fluorescent proteins may be used (e.g. green fluorescent protein (GFP) and the variants thereof from Aequorea victoria and Renilla reniformis or other species; red fluorescent proteins and proteins which fluoresce in other colours and their variants from non-bioluminescent organisms such as e.g.
25 Discosoma sp., Anemonia sp., Clavularia sp., Zoanthus sp.) for the selection of transformed cells.
Gene expression and selection of high-producing host cells 3 o The term gene expression relates to the transcription and/or translation of a heterologous gene sequence in a host cell. The expression rate can be generally determined, either on the basis of the quantity of corresponding mRNA which is present in the host cell or on the basis of the quantity of gene product produced which is encoded by the gene of interest. The quantity of mRNA produced by transcription of a selected nucleotide sequence can be determined for example by northern blot hybridisation, ribonuclease-RNA-protection, in situ hybrisation of cellular RNA or by PCR methods (Sambrook et al., 1989; Ausubel et al., 1994). Proteins which are encoded by a selected nucleotide sequence can also be determined by various methods such as, for example, ELISA, western blot, radioimmunoassay, immunoprecipitation, detection of the biological activity of the protein or by immune staining of the 1 o protein followed by FACS analysis (Sambrook et al., 1989; Ausubel et al., 1994).
The terms "high expression level (or rate), high expression, increased expression or high productivity" refer to the long-lasting and sufficiently high 15 expression or synthesis of a heterologous sequence introduced into a host cell, e.g. of a gene coding for a therapeutic protein. Increased or high expression or a high expression level or rate or a high productivity are present if a cell according to the invention is cultivated by one of the methods according to the invention described here, without gene amplification, and if 2 o this cell produces at least more than roughly 0.5 pg of the desired gene product per day (0.5 pg/cell/day). Increased or high expression or a high expression or rate or a high productivity are also present if the cell according to the invention without prior gene amplification produces at least more than roughly 1.0 pg of the desired gene produce per day (1.0 pg/cell/day).
25 Increased or high expression or a high expression level or rate or high productivity are present in particular if the cell according to the invention without prior gene amplification produces at least more than roughly 1.5 pg of the desired gene product per day (1.5 pg/ cell/day). Increased or high expression or a high expression level or rate or high productivity are present 3 o in particular if the cell according to the invention without prior gene amplification produces at least more than roughly 2.0 pg of the desired gene product per day (2.0 pg/cell/day). Particularly increased or high expression or a particularly high expression level or rate or particularly high productivity are present if the cell according to the invention without prior gene amplification produces at least more than roughly 3.0 pg of the desired gene product per day (3.0 pg/cell/day). By means of a simple gene amplification step, e.g.
using the DHFR/MTX amplification system as described hereinafter the productivities can be increased by a factor of at least 2 to 10, so that the terms "high expression", increased expression" or high productivity" are used in relation to a cell which has been subjected to a gene amplification step if this cell produces at least more than roughly 5 pg of the desired gene product to per day (5 pg/cell/day), preferably at least more than roughly 10 pg/cell/day, more preferably at least more than roughly 15 pg/cell/day , still more preferably at least more than roughly 20 pg/celllday or at least more than roughly 30 pg/cell/day.
High or increased expression, high productivity or a high expression level or rate can be achieved both by using one of the expression vectors according to the invention and by the use of one of the processes according to the invention.
2 o For example, by coexpression of the gene of interest and a modified NPT
gene it is possible to select and identify cells which express the heterologous gene to a high degree. Compared with wtNPT, modified NPT allows more efficient selection of stably transfected host cells with high expression of the heterologous gene of interest.
The present invention thus also relates to a process for expressing at least one gene of interest in recombinant mammalian cells, characterised in that (i) a pool of mammalian cells is transfected with at least one gene of interest and one gene for a modified neomycin phosphotransferase which compared 3 o with the wild-type neomycin phosphotransferase has only 1 to 80% of the activity, preferably only 1 to 60%, more preferably only 1.5 to 30%, most preferably only 1.5 to 26°!°; (ii) the cells are cultivated under conditions which allow expression of the gene or genes of interest and the modified neomycin phosphotransferase gene; (iii) the mammalian cells are cultivated in the presence of at least one selecting agent, preferably 6418, which acts selectively on the growth of the mammalian cells, and gives preference to the growth of those cells which express the modified neomycin phosphotransferase gene; and (iv) the protein or proteins of interest is or are obtained from the mammalian cells or the culture supernatant. Preferably recombinant mammalian cells are used which have been transfected with an expression vector according to the invention.
to The invention also relates to a process for selecting recombinant mammalian cells which express at least one gene of interest, wherein (i) a pool of mammalian cells is transfected with at least one gene of interest and a gene for a modified neomycin phosphotransferase which by comparison with wild-type neomycin phosphotransferase has only 1 to 80% of the activity, preferably only 1 to 60%, more preferably only 1.5 to 30%, most preferably only 1.5 to 26%; (ii) the mammalian cells are cultivated under conditions which allow expression of the gene or genes of interest and the modified neomycin phosphotransferase gene; and (iii) the mammalian cells are 2 o cultivated in the presence of at least one selecting agent, preferably 6418, which acts selectively on the growth of the mammalian cells and gives preference to the growth of those cells which express the modified neomycin phosphotransferase gene.
Particularly preferred are processes for expressing at least one gene of interest and for selecting recombinant cells which express a corresponding gene of interest if a modified NPT gene described in more detail in this application is used, particularly if a modified NPT gene is used which by comparison with the wild-type gene codes for glycine or aspartic acid at 3 o amino acid position 182, for alanine at amino acid position 91, for glycine at amino acid position 198, for alanine, glycine or valine at amino acid position 227, for glycine or asparagine at amino acid position 261 or for isoleucine at amino acid position 240. It is particularly preferred to use the Asp227Va1, Asp227G1y, Asp261G1y, Asp261Asn, Phe24011e or Trp91Ala mutant.
Generally, all the modified neomycin phosphotransferase genes according to the invention mentioned in this patent specification are suitable for such a process. For the preferred neomycin phosphotransferase genes see the section on modified neomycin phosphotransferase genes.
The selection of the cells which express a gene of interest and a modified NPT gene is carried out for example by adding 6418 as selecting agent.
1 o However, it is also possible to use other aminoglycoside antibiotics such as neomycin or kanamycin. The cells according to the invention are preferably cultivated and selected in 200 to 800 :g of 6418 per mL of culture medium. It has proved particularly preferable to add 300 to 700 :g of 6418 per mL of culture medium. The addition of roughly 400 :g of 6418 per mL of culture i5 medium is the most preferred embodiment. Using such a method it is possible to select recombinant cells with a particularly high expression rate.
By comparison with the use of wtNPT, after selection with 400 Ng G418 per ml of culture medium as selectable marker, the cells exhibited a productivity increased by a factor of 1.4 - 2.4 in the case of the GIu182G1y, GIu182Asp 2 o and Va1198G1y mutant, by a factor of 1.6 to 4.1 in the case of the Asp227G1y mutant, by a factor of 2.2 or 4 in the case of the Asp227A1a or Trp91 Ala mutant, by a factor of 5.7 or 7.3 in the case of the Phe24011e or Asp261Asn mutant and even by a factor of 9.3 or 14.6 in the case of the Asp261 Gly or Asp227Va1 mutant. The specific producitivities for the various modified NPT
25 genes are shown in Fig. 6.
The corresponding processes may be combined with a FACS-assisted selection of recombinant host cells which contain, as additional selectable marker, one or more fluorescent proteins (e.g. GFP) or a cell surface marker.
3 o Other methods of obtaining increased expression, and a combination of different methods may also be used, are based for example on the use of (artificial) transcription factors, treatment of the cells with natural or synthetic agents for up-regulating endogenous or heterologous gene expression, improving the stability (half-life) of mRNA or the protein, improving the initiation of mRNA translation, increasing the gene dose by the use of episomal plasmids (based on the use of viral sequences as replication origins, e.g. SV40, polyoma, adenovirus, EBV or BPV), the use of amplification-promoting sequences (Hemann et al., 1994) or in vitro amplification systems based on DNA concatemers (Monaco et al., 1996).
Coupled transcription of the gene of interest and the gene which codes for to the fluorescent protein has proved particularly effective in conjunction with the use of a modified NPT gene as selectable marker. The resulting bicistronic mRNA expresses both the protein/product of interest and the fluorescent protein. On the basis of this coupling of the expression of the protein of interest and the fluorescent protein it is easily possible according to the invention to identify and isolate high-producing recombinant host cells by means of the fluorescent protein expressed, e.g. by sorting using fluorescence activated cell sorting equipment (FACS).
The selection of recombinant host cells which exhibit high vitality and an 2 o increased expression rate of the desired gene product is a multistage process. The host cells which have been transfected with the expression vector according to the invention or optionally cotransfected with another vector, for example, are cultivated under conditions which permit the selection of cells expressing the modified NPT, e.g. by cultivation in the 2 5 presence of a selecting agent such as 6418 in concentrations of 100, 200, 400, 600, 800 :g or more of G418/mL of culture medium. Then the corresponding cells are investigated at least for the expression of the gene which codes for a fluorescent protein and is coupled to the gene of interest, in order to identify and sort out the cells/cell population which exhibit the highest 3 o expression rates of fluorescent protein. Preferably, only the cells which belong to the 10-20% of cells with the highest expression rate of fluorescent protein are sorted out and further cultivated. In practice this means that the brightest 10% of the fluorescent cells are sorted out and further cultivated.
Accordingly, the brightest 5%, preferably the brightest 3% or even the brightest 1 % of the fluorescent cells of a cell mixture can also be sorted out and replicated. In a particularly preferred embodiment only the brightest 0.5% or the brightest 0.1 % of the fluorescent cells are sorted out and replicated.
The selection step may be carried out on cell pools or using pre-sorted cell pools/cell clones. One or more, preferably two or more and especially three or more sorting steps may be carried out, while between the individual sorting steps the cells may be cultivated and replicated for a specific length of time, e.g. roughly two weeks in the case of pools. Figures 11 and 12 show specific productivities after FACS-based sorting with and without a gene amplification step for the mutant Asp227G1y, for example.
The present invention thus relates to a process for obtaining and selecting recombinant mammalian cells which express at least one heterologous gene of interest, characterised in that (i) recombinant mammalian cells are transfected with an expression vector according to the invention; (ii) the 2 o transfected cells are cultivated under conditions which allow expression of the gene or genes of interest, the gene coding for a fluorescent protein and the modified neomycin phosphotransferase gene; (iii) the mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells and gives preference to the growth of those cells which express the modified neomycin phosphotransferase gene; and (iv) the mammalian cells which exhibit a particularly high expression of the fluorescent gene are sorted out by flow-cytometric analysis. If desired steps (ii) to (iv) may be repeated once or several times with the cells obtained in step (iv).
A corresponding process is preferred which is characterised in that the sorted mammalian cells have an average specific productivity, without an additional gene amplification step, of more than 0.5 pg of the desired gene product or products per day and per cell (0.5 pg/cell/day), preferably greater than 1 pg/cell/day, more preferably greater than 2 pg/cell/day, still more preferably greater than 3 pg/cell/day, even more preferably greater than 4 pg/cell/day, for example greater than 5, 6, 7, 8, 9, 10, etc, greater than 15, 20, 25 pg/cell/day, etc.. As mentioned above, the productivity of these cells can be increased by a simple gene amplification step, e.g. using the DHFR/MTX
system, by a factor of at least 2 to 10. This is shown for example in Figure for selection using the NTP mutant Asp227G1y. The specific productivities 1 o were between 20 and 25 pg/cell/day.
Also preferred according to the invention is a process in which suitably sorted cells are replicated and used to prepare the encoded gene product of interest. For this, the selected high producing cells are preferably cultivated in a serum-free culture medium and preferably in suspension culture under conditions which allow expression of the gene of interest. The protein/product of interest is preferably obtained from the cell culture medium as a secreted gene product. If the protein is expressed without a secretion signal, however, the gene product may also be isolated from cell lysates. In 2 0 order to obtain a pure homogeneous product which is substantially free from other recombinant proteins and host cell proteins, conventional purification procedures are carried out. First of all, cells and cell debris are removed from the culture medium or lysate. The desired gene product can then be freed from contaminating soluble proteins, polypeptides and nucleic acids, e.g. by 2 s fractionation on immunoaffinity and ion exchange columns, ethanol precipitation, reversed phase HPLC or chromatography on Sephadex, silica or cation exchange resins such as DEAE. Methods which result in the purification of a heterologous protein expressed by recombinant host cells are known to the skilled man and described in the literature, e.g. by Harris et al., 3 0 1995 and Scopes 1988.
Amplifiable Selectable Marker Gene In addition, the cells according to the invention may optionally also be subjected to one or more gene amplification steps in which they are cultivated in the presence of a selecting agent which leads to amplification of an amplifiable selectable marker gene. This step may be carried out both with cells which express a fluorescent protein and have preferably been pre-sorted once or several times by FACS (preferably in one of the ways described here) and with cells which have not yet been sorted.
to The prerequisite is that the host cells are additionally transfected with a gene which codes for an amplifiable selectable marker. It is conceivable for the gene which codes for an amplifiable selectable marker to be present on one of the expression vectors according to the invention or to be introduced into the host cell by means of another vector.
The amplifiable selectable marker gene usually codes for an enzyme which is needed for the growth of eukaryotic cells under certain cultivation conditions.
For example, the amplifiable selectable marker gene may code for dihydrofolate reductase (DHFR). In this case the gene is amplified if a host 2 o cell transfected therewith is cultivated in the presence of the selecting agent methotrexate (MTX).
The following Table 2 gives examples of other amplifiable selectable marker genes and the associated selecting agents which may be used according to 2 5 the invention, which are described in an overview by Kaufman, Methods in Enzymology, 185:537-566 (1990).
Table 2: Amplifiable selectable marker genes Amplifiable selectableAccession number Selecting agent marker ene dihydrofolate reductaseM19869 (hamster) methotrexate (MTX) E00236mouse _ metallothionein ~D10551 (hamster) cadmium ~

M13003 (human) M 11794 rat CAD (carbamoylphosphateM23652 (hamster) N-phosphoacetyl-L-synthetase : aspartateD78586 (human) aspartate transcarbamylase:

dih droorotase adenosine-deaminase K02567 (human) Xyl-A- or adenosine, M10319 mouse 2'deox coform cin AMP (adenylate)- D12775 (human) adenine, azaserin, deaminase J02811 rat coform cin UMP-s nthase J03626 human 6-azauridine, razofuran IMP 5'-dehydrogenase J04209 (hamster) mycophenolic acid J04208 (human) M33934 mouse xanthine-guanin- X00221 (E. coli) mycophenolic acid with hos horibos Itransferase limitin xanthine mutant HGPRTase or J00060 (hamster) hypoxanthine, mutant thymidine-kinaseM13542, K02581 aminopterine and (human) thymidine (HAT) J00423, M68489(mouse) M63983 (rat) M36160 Her es virus thymidylate-synthetaseD00596 (human) 5-fluorodeoxyuridine M13019 (mouse) L12138 rat P-glycoprotein 170 AF016535 (human) several drugs, e.g.
(MDR1 ) J03398 (mouse) adriamycin, vincristin, colchicine ribonucleotide reductaseM124223, K02927 aphidicoline mouse glutamine-synthetase AF150961 (hamster) methionine sulphoximine U09114, M60803 (MSX) (mouse) M29579 rat asparagine-synthetase M27838 (hamster) ~-aspartylhydroxamate, M27396 (human) albizziin, 5'azacytidine U38940 (mouse) U07202 rat argininosuccinate- X01630 (human) canavanin synthetase M31690 (mouse) M26198 bovine ornithine-decarboxylaseM34158 (human) a-difluoromethylornithine J03733 (mouse) M 16982 rat HMG-CoA-reductase L00183,M12705 compactin hamster M11058 human N-acetylglucosaminyl- M55621 (human) tunicamycin transferase threon I-tRNA-s nthetaseM63180 human borrelidin Na+K+-ATPase J05096 (human) ouabain M14511 rat According to the invention the amplifiable selectable marker gene used is preferably a gene which codes for a polypeptide with the function of DHFR, e.g. for DHFR or a fusion protein from the fluorescent protein and DHFR.
DHFR is necessary for the biosynthesis of purines. Cells which lack the DHFR genes cannot grow in purine-deficient medium. The DHFR gene is therefore a useful selectable marker for selecting and amplifying genes in cells cultivated in purine-free medium. The selecting medium used in conjunction with the DHFR gene is methotrexate (MTX).
to The present invention therefore includes a method of preparing and selecting recombinant mammalian cells which contains the following steps: (i) transfection of the host cells with genes which code at least for a protein/
product of interest, a modified neomycin phosphotransferase and DHFR; (ii) cultivation of the cells under conditions which allow expression of the various genes; and (iii) the amplification of the co-integrated genes by cultivating the cells in the presence of a selecting agent which allows the amplification of at least the amplifiable selectable marker gene such as methotrexate.
Preferably the transfected cells are cultivated in hypoxanthine/thymidine-free 2 o medium in the absence of serum and with the addition of increasing concentrations of MTX. Preferably the concentration of MTX in the first amplification step is at least 5 nM. The concentration of MTX may, however, also be at least 20 nM or 100 nM and be increased step by step to 1 :M. In individual cases concentrations of more than 1 :M may be used, e.g. 2 :M.
If the corresponding cells are additionally transformed with a gene for a fluorescent protein, these cells may be identified and sorted using a fluorescence activated cell sorting device (FACS) and then cultivated in a gene amplification step in the presence of at least 20, preferably in the presence of 50 or 100 nM MTX. In this way it is possible to increase productivities substantially to more than 20 pg of gene product per cell and per day, preferably to more than 21, 22, 23, 24, 25, etc., 30, 35, 40, etc..
The host cells may be subjected to one or more gene amplification steps in order to increase the copy number of at least the gene of interest and the amplifiable selectable marker gene. According to the invention the high productivity which can be achieved is linked to effective pre-selection by means of neomycin phosphotransferase- mediated resistance to 1 o aminoglycoside antibiotics such as neomycin, kanamycin and 6418. It is therefore possible to reduce the number of gene amplification steps required and to carry out only a single gene amplification, for example.
In a further embodiment the present invention thus also relates to processes 1 s for obtaining and selecting recombinant mammalian cells which express at least one heterologous gene of interest and are characterised in that (i) recombinant mammalian cells are transfected with an expression vector according to the invention and the gene for an amplifiable selectable marker gene; (ii) the mammalian cells are cultivated under conditions which allow 2 o expression of the gene or genes of interest, the modified neomycin phosphotransferase gene and the gene which codes for a fluorescent protein;
(iii) the mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells and gives preference to the growth of those cells which express the neomycin 25 phosphotransferase gene; (iv) the mammalian cells which exhibit high expression of the fluorescent protein are sorted out by flow-cytometric analysis; (v) the sorted cells are cultivated under conditions under which the amplifiable selectable marker gene is expressed; and (vi) a selecting agent is added to the culture medium which results in the amplification of the 3 o amplifiable selectable marker gene.

Particularly preferred is a corresponding process in which the modified neomycin phosphotransferase genes described in this invention are used.
Also preferred is a process in which only one amplification step is carried out.
Also preferred is a corresponding process which leads to recombinant mammalian cells which exhibit an average specific productivity of more than 20 pg, preferably more than 21, 22, 23, 24, 25, etc., 30, 35, 40, etc..of the desired gene product or products per cell and per day.
Mammalian cells, preferably mouse myeloma and hamster cells, are 1 o preferred host cells for the use of DHFR as an amplifiable selectable marker.
The cell lines CHO-DUKX (ATCC CRL-9096) and CHO-GD44 (Urlaub et al., 1983) are particularly preferred as they have no DHFR activity of their own, as a result of mutation. In order to be able to use the DHFR-induced amplification in other cell types as well which have their own endogenous DHFR activity, it is possible to use in the transfection process a mutated DHFR gene which codes for a protein with reduced sensitivity to methotrexate (Simonson et al., 1983; Wigler et al., 1980; Haber et al., 1982).
The DHFR marker is particularly suitable for the selection and subsequent 2 o amplification when using DHFR negative basic cells such as CHO-DG44 or CHO-DUKX, as these cells do not express endogenous DHFR and therefore do not grow in purine-free medium. Consequently, the DHFR gene may be used here as a dominant selectable marker and the transformed cells are selected in hypoxanthine/ thymidine-free medium.
The invention is described more fully hereinafter with reference to some non-restrictive examples.
3 o EXAMPLES
Abbreviations Ala (=A) alanine AP: alkaline phosphatase Asn (=N) asparagine s Asp (=D):aspartic acid bp: base pair BSA: bovine serum albumin CHO: Chinese Hamster Ovary dhfr: dihydrofolate-reductase to DMSO: dimethylsulphoxide ELISA: enzyme-linked immunosorbent assay FRCS: fluorescence-activated cell sorter FITC: fluoresceine-isothiocyanate GFP: green fluorescent protein 1 Glu (=E):glutamic acid s Gly (=G):glycine HBSS: Hanks Balanced Salt Solution HT: hypoxanthine/thymidine Ile (=I):isoleucine 2o IRES: internal ribosomal entry site kb: kilobase mAb: monoclonal antibody MCP-1: monocyte chemoattractant protein-1 MTX: methotrexate 2 MW: mean value s NPT: neomycin-phosphotransferase PCR: polymerase chain reaction PBS: phosphate buffered saline Phe (=F):phenylalanine 3 Trp (=W):tryptophan o Val (=V):valine WT: wild-type Methods 1. Cell culture and Transfection s The cells CHO-DG44/dhfr~- (Urlaub et al., 1983) were permanently cultivated as suspension cells in serum-free CHO-S-SFMII medium supplemented with hypoxanthine and thymidine (Invitrogen GmbH, Karlsruhe, DE) in cell culture flasks at 37°C in a damp atmosphere and 5% C02. The cell counts and viability were determined with a CASY1 Cell Counter (Schaerfe System, DE) l o or by tryptan blue staining and the cells were then seeded in a concentration of 1 - 3 x105/mL and run every 2 - 3 days.
Lipofectamine Plus Reagent (Invitrogen GmbH) was used for the transfection of CHO-DG44. For each transfection mixture a total of 1 Ng of plasmid-DNA, 4 pL of lipofectamine and 6 NL of Plus reagent were mixed together 15 according to the manufacturer's instructions and added in a volume of 200 NL to 6 x105 exponentially growing CHO-DG44 cells in 0.8 mL of HT-supplemented CHO-S-SFMII medium. After three hours' incubation at 37°C
in a cell incubator 2 mL of HT-supplemented CHO-S-SFMII medium was added.
For the NPT-based selection the cells were transferred 2 days after 2o transfection into HT-supplemented CHO-S-SFMII medium with 6418 (Invitrogen), changing the medium every 3 to 4 days. As a rule, 400 pg/mL of 6418 were added for the selection and in some experimental series the concentration was also lowered to 200 pg/mL or raised to 500, 600 or 800 Ng/mL. In DHFR- and NPT-based selection in the event of co-transfection, in 25 which one expression vector contained a DHFR and the other expression vector contained a neomycin-phosphotransferase selectable marker, the cells were transferred 2 days after transfection into CHO-S-SFMII medium without the addition of hypoxanthine and thymidine and also 6418 (Invitrogen) was added to the medium in a concentration of 400Ng/mL.

A DHFR-based gene amplification of the integrated heterologous genes can be obtained by the addition of the selecting agent MTX (Sigma, Deisenhofen, DE) in a concentration of 5 - 2000 nM to an HT-free CHO-S-SFMII medium.
s 2. Expression vectors To analyse the expression, eukaryotic expression vectors were used which are based on the pAD-CMV vector (Werner et al., 1998) and mediate the constitutive expression of a heterologous gene by the combination of CMV
enhancer/hamster ubiquitin/S27a promoter (WO 97/15664). While the base to vector pBID contains the dhfr-minigene which acts as an amplifiable selectable marker (cf e.g. EP-0-393-438), in the vector pBIN the dhfr-minigene has been replaced by a neomycin-phosphotransferase resistance gene (Fig.1 ). For this purpose the selectable marker neomycin-phosphotransferase, including SV40 early promoter and TK-polyadenylation 1 s signal, was isolated from the commercial plasmid pBK-CMV (Stratagene, La Jolla, CA, USA) as a 1640 by Bsu361 fragment. After a reaction to fill in the ends of the fragment with Klenow-DNA-polymerase the fragment was ligated with the 3750 by Bsu361/Stul fragment of the vector pBID, which was also treated with Klenow-DNA-polymerase.
In the bicistronic base vector pBIDG (Fig. 1 ) the IRES-GFP gene region was isolated from the vector pIRES2-EGFP (Clontech, Palo Alto, CA, USA) and brought under the control of the CMV enhancer/promoter in the vector pBID
so that the multiple cloning site between the promoter region and IRES-element was retained. The following procedure was used. In a PCR
mutagenesis in which the plasmid pIRES2-EGFP acted as the template, on the one hand the Hindlll cutting site AAGCTT within the IRES sequence was converted into the sequence ATGCTT by the use of mutagenic primers and thus eliminated. On the other hand an Xbal cutting site was inserted by 3 o means of a primer with complementarity to the 5'end of the IRES sequence or a Spel cutting site was introduced by means of a primer with complementarity to the 3'end of the GFP sequence. The resulting PCR

fragment, which contained the complete IRES and GFP sequence, was digested with Xbal and Spel and cloned into the singular Xbal cutting site at the 3'end of the multiple cloning site of the vector pBID. In the same way the IRES-GFP gene region from the vector pIRES2-EGFP was brought under the s control of the CMV enhancer/hamster ubiquitin/S27a promoter in the vector pBIN. This produced the bicistronic base vector pBING (Fig.1 ).
Human MCP-1 cDNA (Yoshimura et al., 1989) was cloned into the corresponding cutting sites of the vector pBIN as a 0.3 kb Hindlll/EcoRl to fragment, resulting in the vector pBIN-MCP1 (Fig. 2A).
In order to express a monoclonal humanised IgG2 antibody the heavy chain was cloned as a 1.5 kb BamHl/Hindlll fragment into the vector pBID or pBIDG digested with BamHl and Hindlll, to obtain the vector pBID-HC or 15 pBIDG-HC (Fig. 2B). The light chain on the other hand was cloned as a 0.7 kb BamHl/Hindlll fragment into the corresponding cutting sites of the vector pBIN or pBING, producing the vector pBIN-LC or pBING-LC (Fig. 2B) .
3. FA CS
2 o The flow-cytometric analyses and sorting were carried out with a Coulter Epics Altra device. The FACS is fitted with a helium-argon laser with an excitation wavelength of 488 nm. The fluorescence intensity is absorbed at a wavelength suited to the fluorescence protein and process by means of the attached software Coulter Expo32. The sorting is normally carried out at a 2 s rate of 8000 - 10000 events/second. The suspended cells can be centrifuged (5 min at 180xg) and adjusted to a cell concentration of 1 - 1.5 x107/mL in HBSS. Then the cells can be sorted according to their fluorescence protein signal. The cells are taken up in test tubes already containing culture medium, then centrifuged and, depending on the number of cells sorted, 3 o seeded into suitable culture vessels or deposited directly in microtitre plates.
4. ELISA

The MCP-1 titres in supernatants of stably transfected CHO-DG44 cells were quantified by ELISA using the OptEIA Human MCP-1 Set kit in accordance with the manufacturer's instructions (BD Biosciences Pharmingen, Heidelberg, DE).
The IgG2 mAb in the supernatants from stably transfected CHO-DG44 cells was quantified by ELISA according to standard procedures (Current Protocols in Molecular Biology, Ausubel et al., 1994, updated), using on the one hand a goat anti human IgG Fc fragment (Dianova, Hamburg, DE) and on the other hand an AP-conjugated goat anti human kappa light chain 1 o antibody (Sigma). Purified IgG2 antibody was used as the standard.
Productivities (pg/cell/day) were calculated by the formula pg/((Ct-Co) t / In (Ct-Co)), where Co and Ct are the cell count on seeding and harvest, respectively, and t is the cultivation time.
5. Dot Assay for determining the NPT enzyme activity In order to prepare a cell extract according to a method of Duch et al., 1990, 6x106 cells were washed twice with PBS and then resuspended in 600 pL of extraction buffer (0.135 M Tris-HCI pH 6.8, 20% glycerol, 4 mM
dithiothreitol).
After four cycles of freezing and thawing in a bath of dry ice or water the cell 2 o debris was removed by centrifuging and the supernatant was used for the subsequent enzyme assay. The protein concentration in the cell extracts was determined by a Bradford assay using the BIO-RAD protein assay (Bio-Rad Laboratories GmbH, Munich, DE), with BSA as the standard protein (Current Protocols in Molecular Biology, Ausubel et al., 1994, updated). In order to determine the NPT enzyme activity a Dot Assay was carried out, based on the protocol of Platt et al. 1987. For this, 5 Ng, 2.5 Ng and 1.25 Ng of protein were adjusted with extraction buffer to a final volume of 20 pL, topping up to a total protein content of 5 Ng with cell extract from non-transfected CHO-DG44 cells. After the addition of 200 NL of assay buffer (67 mM Tris-HCI pH
3 0 7.1, 42 mM MgCl2, 400 mM NH4CI) plus/minus 40 Ng/mL 6418 and plus/minus 5 NCi [y-33P]-ATP/mL (NEN) the extracts were incubated at 27°C
for 135 minutes. Then the extracts were filtered in a 96 well vacuum manifold (Schleicher & Schiall, Dassel, DE) through a sandwich of one layer of Whatman 3MM paper, P81 phosphocellulose membrane (Whatman Laboratory Division, Maidstone, Great Britain) and nitrocellulose membrane (Schleicher & Schull). Proteins phosphorylated by protein kinases and non-phosphorylated proteins bind to the nitrocellulose, while phosphorylated 6418 passes through the nitrocellulose and binds to the phosphocellulose.
After washing three times with deionised H20 the membranes were removed from the apparatus, washed again with H20 and then air-dried. The radioactive signals were quantified using a Phospho Imager (Molecular 1 o Dynamics, Krefeld, DE).
6. Northern Blot Analysis Total RNA was isolated from the cells with the TRIZOL reagent according to the manufacturer's instructions (Invitrogen GmbH, Karlsruhe, DE) and the 1 s separation of 30 Ng RNA by gel electrophoresis and the transfer to a Hybond N+ nylon membrane (Amersham Biosciences, Freiburg, DE) were carried out according to the standard procedure for glyoxal/DMSO-denatured RNA
(Current Protocols in Molecular Biology, Ausubel et al., 1994, updated). The probe used for the subsequent non-radioactive hybridisation with the 2 o Genelmages CDP-Star Detection Kit (Amersham Biosciences) was a PCR
product which comprised the coding region of the NPT gene, FITC-dUTP-labelled according to the manufacturer's instructions with the Genelmages random prime labelling kit (Amersham Biosciences, Freiburg, DE).
2 s 7. Dot Blof Analysis Genomic DNA was isolated from the cells using a DNA isolation kit according to the manufacturer's instructions (DNA Isolation Kit for Cells and Tissue;
Roche Diagnostics GmbH, Mannheim, DE). Various amounts of DNA (10 Ng, Ng, 2.5 pg, 1.25 Ng, 0.63 Ng and 0.32 Ng) were filtered by the standard 3 o method (Ausubel et al., 1994) in an alkaline buffer using a 96 well vacuum manifold (Schleicher & Schull, Dassel, DE) onto a Hybond N+ nylon membrane (Amersham Biosciences, Freiburg, DE). Untransfected CHO-DG44 cells were used as the negative control. The plasmid pBIN-LC was used as the standard (320 pg, 160 pg, 80 pg, 40 pg, 20 pg, 10 pg, 5 pg, 2.5 pg). The probe used for the subsequent non-radioactive hybridisation with the Genelmages CDP-Star Detection Kit (Amersham Biosciences) was a PCR
s product which comprised the coding region of the NPT gene, FITC-dUTP-labelled according to the manufacturer's instructions with the Genelmages random prime labelling kit (Amersham Biosciences, Freiburg, DE). The chemiluminescence signals were quantified using an ImageMaster VDS-CL
(Amersham Biosciences). Then the copy number of the npt genes in the cells 1 o in question was determined using the standard series which had been obtained from the signal intensities of the titrated plasmid DNA. The number of plasmid molecules was calculated using Avogadro's constant and the DNA
content of a CHO cell was taken to be about 5 pg.
Example 1: Mutagenesis of the neomycin-phosphotransferase The base substitutions in the wild-type NPT-gene needed to prepare the NPT
mutants GIu182G1y (SEQ ID N0:3), Trp91Ala (SEQ ID N0:5), Va1198G1y (SEQ ID N0:7), Asp227A1a (SEQ ID N0:9), Asp227Va1 (SEQ ID N0:11), Asp261G1y (SEQ ID N0:13), Asp261Asn (SEQ ID N0:15) Phe24011e (SEQ ID
N0:17), GIu182Asp (SEQ ID N0:19), Asp227G1y (SEQ ID N0:21 ), Asp190G1y (SEQ ID N0:23) and Asp208G1y (SEQ ID N0:25) were carried out by PCR using mutagenic primers (Fig. 3). The vector pBIN (Fig. 1 ) or 2 s pBK-CMV (Stratagene, La Jolla, USA) was used as a template for the PCR
mutagenesis. First, the 5' or 3'sections of the mutants were prepared in separate PCR operations. To prepare the mutants GIu182G1y, GIu182Asp, Trp91 Ala, Asp190G1y, Va1198G1y, Asp208G1y and Asp227G1y, primer combinations were used for the amplification which consisted of Neofor5 (SEQ ID N0:27) and the relevant mutagenic reverse (rev) primer or Neorev5 (SEQ ID N0:28) and the relevant mutagenic forward (for) primer:

- In the case of NPT mutant GIu182G1y (SEQ ID N0:3) of Neofor5 (SEQ ID
N0:27) and E182Grev (SEQ ID N0:32) or of Neorev5 (SEQ ID N0:28) and E182Gfor (SEQ ID N0:31 );
- in the case of the NPT mutant GIu182Asp (SEQ ID N0:19) of Neofor5 s (SEQ ID N0:27) and E182Drev (SEQ ID N0:48) or of Neorev5 (SEQ ID
N0:28) and E182Dfor (SEQ ID N0:47);
- in the case of the NPT mutant Trp91Ala (SEQ ID N0:5) of Neofor5 (SEQ
ID N0:27) and W91Arev (SEQ ID N0:34) or of Neorev5 (SEQ ID N0:28) and W91Afor (SEQ ID N0:33);
to - in the case of the NPT mutant Va1198G1y (SEQ ID N0:7) of Neofor5 (SEQ
ID N0:27) and V198Grev (SEQ ID N0:36) or of Neorev5 (SEQ ID N0:28) and V198Gfor (SEQ ID N0:35) - in the case of the NPT mutant Asp190G1y (SEQ ID N0:23) of Neofor5 (SEQ ID N0:27) and D190Grev (SEQ ID N0:50) or of Neorev5 (SEQ ID
15 N0:28) and D190Gfor (SEQ ID N0:49);
- in the case of the NPT mutant Asp208G1y (SEQ ID N0:25) of Neofor5 (SEQ ID N0:27) and D208Grev (SEQ ID N0:52) or of Neorev5 (SEQ ID
N0:28) and D208Gfor (SEQ ID N0:51 );
- in the case of the NPT mutant Asp227G1y (SEQ ID N0:21 ) of Neofor5 20 (SEQ ID N0:27) and D227Grev (SEQ ID N0:54) or of Neorev5 (SEQ ID
N0:28) and D227Gfor (SEQ ID N0:52).
In order to prepare the mutants Asp227A1a, Asp227Va1, Asp261 Gly, Asp261Asn and Phe24011e primer combinations were used for the 2s amplification which consisted of Neofor2 (SEQ ID N0:29) and the relevant mutagenic reverse (rev) primer or of IC49 (SEQ ID N0:30) and the relevant mutagenic forward (for) primer:
- In the case of NPT mutant Asp227A1a (SEQ ID N0:9) of Neofor2 (SEQ ID
N0:29) and D227Arev (SEQ ID N0:38) or of IC49 (SEQ ID N0:30) and 3o D227Afor (SEQ ID N0:37);

- in the case of NPT mutant Asp227Va1 (SEQ ID N0:11 ) of Neofor2 (SEQ
ID N0:29) and D227Vrev (SEQ ID N0:40) or of IC49 (SEQ ID N0:30) and D227Vfor (SEQ ID N0:39);
- in the case of NPT mutant Asp261 Gly (SEQ ID N0:13) of Neofor2 (SEQ
ID N0:29) and D261Grev (SEQ ID N0:42) or of IC49 (SEQ ID N0:30) and D261 Gfor (SEQ ID N0:41 );
- in the case of NPT mutant Asp261Asn (SEQ ID N0:15) of Neofor2 (SEQ
ID N0:29) and D261 Nrev (SEQ ID N0:44) or of IC49 (SEQ ID N0:30) and D261 Nfor (SEQ ID N0:43);
to - in the case of NPT mutant Phe24011e (SEQ ID N0:17) of Neofor2 (SEQ ID
N0:29) and F2401rev (SEQ ID N0:46) or of IC49 (SEQ ID N0:30) and F2401for (SEQ ID N0:45).
Then the coding strand of the 5'section and the complementary strand of the 3'section of the mutants in question were combined by hybridisation in the overlapping region formed by the mutagenic primer sequences, the single strand regions were filled in and the entire product was amplified again in a PCR with the primers Neofor5 (SEQ ID N0:27) and Neorev5 (SEQ ID N0:28) or Neofor2 (SEQ ID N0:29) and IC49 (SEQ ID N0:30). These PCR products 2o were digested with Stul/Rsrll (Neofor5/Neorev5 PCR-products of the mutants GIu182G1y, Trp91Ala and Va1198G1y), Stul/BstBl (Neofor5/Neorev5 PCR
products of the mutants GIu182Asp, Asp190G1y, Asp208G1y and Asp227G1y) or Dralll/Rsrll (Neofor2/IC49 PCR products of the mutants Asp227A1a, Asp227Va1, Asp261 Gly, Asp261 Asn and Phe24011e). Then in the vector pBIN-LC (Fig. 2B) or pBK-CMV (Stratagene, La Jolla, USA) part of the wild-type NPT sequence was eliminated by Stul/Rsrll digestion, Dralll/Rsrll digestion or Stul/BstBl digestion and replaced by the corresponding fragments of the PCR products. By sequence analysis of both the complementary and the coding strand the desired base substitutions in the 3 o various mutants were verified to ensure that the remaining DNA sequence corresponded to the wild-type NPT sequence. In this way the expression vectors pBIN1-LC, pBIN2-LC, pBIN3-LC, pBIN4-LC, pBINS-LC, pBIN6-LC, pBIN7-LC and pBINB-LC were generated, which contain the NPT mutants GIu182G1y, Trp91 Ala, Va1198G1y, Asp227A1a, Asp227Va1, Asp261 Gly, Asp261 Asn or Phe24011e (Fig. 2B).
The remaining NPT mutants were isolated as a 1640 by Bsu361 fragment from the modified pBK-CMV, the fragment ends were filled in with Klenow-DNA polymerase and ligated with the 3750 by Bsu361/Stul fragment of the vector pBID, which was also treated with Klenow-DNA polymerase. In this way the expression vectors pKS-N5, pKS-N6, pKS-N7 and pKS-N8 were to generated which contained the NPT mutants GIu182Asp, Asp190G1y, Asp208G1y and Asp227G1y, respectively. The human MCP-1 cDNA was then cloned into these expression vectors as a 0.3 kb Hindlll/EcoRl fragment (Fig.
2A) or the light chain of the humanised IgG2 antibody was cloned into these expression vectors as a 0.7 kb Hindlll/BamHl fragment (Fig. 2B).
The mutations inserted in the neomycin phosphotransferase are on the one hand substitutions of more (Va1198G1y, Phe24011e) or less (Trp9lAla, GIu182G1y, GIu182Asp, Asp227A1a, Asp227Va1, Asp227G1y) conserved amino acids which flank conserved domains, such as e.g. the motifs 1, 2 and 2 0 3 (Shaw et al., 1993) (Fig. 4). On the other hand the mutations are located within the conserved motif 1 (Asp190G1y), 2 (Asp208G1y) or 3 (Asp261 Gly, Asp261Asn) and relate to a conserved amino acid.
Example 2: Influence of the NPT mutations on the selection of stably 2 5 transfected MCP-1 expressing cells MCP was used as an example of the expression of a single chained protein in CHO cells. For this, CHO-DG44 was transfected with pKS-N5-MCP1, pKS-N6-MCP1, pKS-N7-MCP1, pKS-N8-MCP1 or pBIN-MCP1 (Fig. 2A).
3 o Two double preparations were carried out. Two days after transfection the cells were seeded in a 96 well-plate (2000 cells/well) and selected with 400 pg/mL of 6418 in HT-supplemented CHO-S-SFMII medium. In the case of the cells transfected with pBIN-MCP1 selection was also carried out in parallel with 800 pg/mL of 6418. The cell populations obtained were successively transferred via 24 well plates into 6 well plates. Even during the selection phase differences could be detected between the various transfection mixtures. In contrast to the cell populations in which selection had been carried out with an NPT wild-type gene (SEQ ID N0:1 ), in those cell populations which had been transfected with a mutated NPT, fewer cells survived the initial selection with 6418. These cell populations therefore could not be transferred into the 24 well plates until about four days later.
to And in the mixtures which has been transfected with pKS-N6-MCP1 and pKS-N7-MCP1 no stably transfected cells whatever could be selected at a concentration of 400 Ng/mL of 6418. Presumably, the enzyme function is so severely impaired in the NPT mutants with the mutations Asp190G1y and Asp208G1y that not enough 6418 molecules can be inactivated to allow growth of the stably transfected cells. Admittedly, when the 6418 concentration was reduced to 200 Ng/mL, a few cells survived the first selection phase, but they were all severely impaired in their growth and vitality and expansion was not possible, apart from a few exceptions in the case of the mutant Asp208G1y.
From the cells transfected with the mutants GIu182Asp and Asp227G1y or with the NPT wild-type, 18 pools were cultivated (9 pools each of mixtures 1 and 2) over four passages in 6 well plates and the concentration of the MCP-1 produced was measured in the cell culture supernatant by ELISA. Cell 2 5 pools in which the NPT mutants had been used as selectable markers showed on average 50% - 57% (GIu182Asp mutant) or 57% - 65%
(Asp227G1y mutant) higher productivities than cell pools in which the selection had been carried out with the NPT wild-type at 400 or even 800 Ng/mL of 6418 (Fig. 5). Thus, by using NPT mutants as selectable markers 3 o the proportion of high producers in the transfected cell populations could actually be increased.

Example 3: Influence of the NPT mutations on the selection of stably transfected mAb expressing cells In a co-transfection CHO-DG44 cells were transfected first with the plasmid combination pBIDG-HC/pBIN-LC (NPT wild-type), pBIDG-HC/pKS-N5-LC
(GIu182Asp NPT mutant) or pBIDG-HC/pKS-N8-LC (Asp227G1y NPT mutant) (Fig. 2B). In the vector confirgurations used the two protein chains of a humanised IgG2 antibody are each expressed by their own vector which additionally codes for a DHFR or neomycin selectable marker in a separate to transcription unit. The expression of the product genes is mediated by a CMV-Enhancer/Hamster Ubiquitin/S27a Promoter combination. However, comparable data may also be obtained, for example, using a CMV
Enhancer/Promoter, an SV40 Enhancer/Hamster Ubiquitin/S27a Promoter or other promoter combinations.
In all, four series of transfections were carried out in each case using 6 pools per plasmid combination. By contrast to the cell populations in which selection was carried out with an NPT wild-type gene, in those cell populations which had been transfected with a mutated NPT, fewer cells 2 o survived the initial selection with 6418. After two to three weeks' selection of the transfected cell pools in HT-free CHO-S-SFMII medium with the additional 400 Ng/mL of 6418, the antibody titre in the cell culture supernatants was determined by ELISA over several runs (6 - 8). By comparison with the use of an NPT wild-type gene as selectable marker, the 2s cells which has been selected with the GIu182Asp mutant showed on average an increase in productivity and titre of 86% and 77%, respectively, and the cells selected with the Asp227G1y mutant even showed an increase in productivity and titre of 126% and 107%, respectively. Thus, by using an NPT mutant with reduced enzyme activity it was possible to selectively enrich 3 o cells having a basic productivity which was up to twice as high.

In another transfection series the influence of different concentrations of 6418 on selection was tested. 400, 500 and 600 pg/mL of 6418 were used for the selection of the transfected cell pools, 3 pools in each case. At the higher concentrations, significantly fewer cells survived the selection in the s cell populations in which selection has been carried out with an NPT wild-type gene, the effect being greatest with the Asp227G1y mutant. The stably transfected cell populations obtained, however, showed no deterioration in growth and vitality. However, no significant difference could be detected between the productivities and titres achieved within a plasmid combination to used for transfection. But, even here, the cells selected by the NPT
mutants again had the highest productivities on average, led by the Asp227G1y mutant, the productivity of which was four times higher than that of the NPT
wild-type, followed by the GIu182Asp mutant with a productivity 2.4 times higher (Fig. 6A).
Then in a co-transfection CHO-DG44 cells were transfected with the plasmid combination pBIDG-HC/pBIN-LC (NPT wild-type), pBIDG-HC/pBIN1-LC
(GIu182G1y NPT mutant), pBIDG-HC/pBIN2-LC (Trp91Ala NPT mutant), pBIDG-HC/pBIN3-LC (Va1198G1y NPT mutant), pBIDG-HC/pBIN4-LC
(Asp227A1a), pBIDG-HC/pBINS-LC (Asp227Va1 NPT mutant), pBIDG-HC/pBIN6-LC (Asp261G1y NPT mutant), pBIDG-HC/pBIN7-LC (Asp261Asn NPT mutant) or pBIDG-HC/pBINB-LC (Phe24011e NPT mutant) (Fig. 2B). In the vector configurations used, again the two protein chains of a monoclonal humanised IgG2 antibody were each expressed by their own vector, which 2s additionally also codes for a DHFR or neomycin selectable marker in a separate transcription unit.
For each plasmid combination, 5 pools were transfected. In contrast to the cell populations in which selection was done with an NPT wild-type gene, 3 o fewer cells survived the initial selection with 6418 in the cell populations which had been transfected with a mutated NPT. After a two- to three-week selection of the transfected cell pools in HT-free CHO-S-SFMII medium with the addition of 400 Ng/mL of 6418 the antibody titre in the cell culture supernatants was determined by ELISA over six runs. Fig. 6B shows the averages of the titres and productivities determined from the pools in the test.
Compared with the use of an NPT wild-type gene as the selectable marker, s all the cell pools which had been selected with an NPT mutant showed on average an increase in productivity and titre by a factor of 1.4 - 14.6 and 1.4 - 10.8, respectively (Fig. 6B). The best selective enrichment of cells with a higher basic productivity could thus be obtained with the NPT mutants Asp227Va1 and Asp261 Gly, with increases in average productivity by a factor l o of 14.6 and 9.3, respectively.
The vector pBIDG-HC contains another selectable marker, GFP. The GFP is transcriptionally linked to the heavy chain via an IRES element. The resulting correlation between the expression of the target protein and the selectable 15 marker GFP therefore also makes it possible to rapidly evaluate the level and distribution of the expression levels in the transfected cell populations on the basis of the GFP fluorescence determined in FACS analyses. After two to three weeks' selection of the transfected cell pools in HT-free CHO-S-SFMII
medium with the addition of 6418 the GFP fluorescence was measured in a 2 o FACS analysis (Fig. 7). The GFP fluorescence signals in fact correlated with the titre data obtained for the monoclonal IgG2 antibody. Pools selected with the NPT mutants Asp227Va1, Asp261G1y, Asp161Asn and Phe24011e also had the higher proportion of cells with a high GFP fluorescence, followed by the cells selected with the NPT mutants Trp91Ala, Asp227A1a, Asp227G1y, 2s GIy182Asp, GIu182G1y and Va1198G1y.
By adding the selection agent methotrexate (MTX) to the culture medium it was possible to increase the productivity of the cells still further by inducing a dhfr-mediated gene amplification. Thus, for example, after a simple gene 3 o amplification step with 100 nM MTX, the specific productivity in the cells pools obtained by a co-transfection with the plasmid combinations pBIDG-HC/pBINS-LC (NPT mutant Asp227Va1), pBIDG-HC/pBIN6-LC (NPT mutant Asp261G1y), pBIDG-HC/pBIN7-LC (NPT mutant Asp261Asn) and pBIDG-HC/pBINB-LC (NPT mutant Phe24011e) could be increased by a factor of 2 to 4 and, depending on the pool, productivities of between 4 and 14 pg/cell/day could be achieved. Figure 8 shows, by way of example, on a cell pool obtained by the co-transfection of pBIDG-HC/pBINS-LC (NPT mutant Asp227Va1), the increases in productivity to 27 pg/cell/day achieved by the addition of MTX (100 nM MTX followed by 500 nM MTX).
Example 4: Determining and comparing the NPT enzyme activity In order to compare the enzyme activity of the NPT mutants with that of the NPT wild-type a dot assay was carried out to determine the NPT activity in cell extracts, based on the procedure of Platt et al. 1987 and shown by way of example in Fig. 9A for the NPT mutants GIu182Asp and Asp227G1y. Cell extracts were prepared from two different mAb-expressing cell pools which had been transfected and selected either with the NPT wild-type gene (SEQ
ID N0:1 ) or with the NPT mutants GIu182G1y (SEQ ID N0:3), G1u182Asp (SEQ ID N0:19), Trp91Ala (SEQ ID N0:5), Asp190G1y (SEQ ID N0:23), Va1198G1y (SEQ ID N0:7), Asp208G1y (SEQ ID N0:25), Asp227A1a (SEQ ID
2 o N0:9), Asp227Va1 (SEQ ID N0:11 ), Asp227G1y (SEQ ID N0:21 ), Asp261 Gly (SEQ ID N0:13), Asp261Asn (SEQ ID N0:15) or Phe24011e (SEQ ID N0:17).
Cell extracts from untransfected CHO-DG44 cells were used as the negative control.
2 5 The enzyme activities of the NPT mutants were significantly reduced, compared with the NPT wild-type. On average the NPT mutants had only between 1.5% and 62% of the wild-type enzyme activity, while the NPT
mutants Asp261 Gly and Asp261 Asn with 3.1 % and 1.5% had the lowest residual activity and the NPT mutants Va1198G1y and Trp91Ala with 61.9%
3 o and 53.2% has the highest residual activity (Fig. 9B). The signals obtained on the phosphocellulose were specific to the phosphorylation of 6418 caused by the NPT enzyme activity. Without the addition of the NPT substrate 6418 to the assay buffer no activity could be detected on the phosphocellulose. The signals obtained on the nitrocellulose membrane, which resulted from the proteins phosphorylated by protein kinases within the cell extract, were used as an internal control for identical amounts of sample applied.
The reduced enzyme activity of the NPT mutants compared with the NPT
wild-type could not be put down to reduced gene expression. On the contrary, Northern Blot analyses on total RNA showed that cell pools which had been transfected with the NPT wild-type and exhibited a high NPT enzyme activity 1 o expressed less RNA than cell pools transfected with NPT mutants (Fig. 10).
The only exception were cells which had been transfected with the NPT
mutant GIu182G1y and expressed comparable amounts of NPT-mRNA. In dot blot analyses carried out on genomic DNA from these transfected cell populations it was shown that the higher expression of the NPT mutants was obtained by gene dose effects and/or by integration of the exogenous DNA
into more transcription-active genomic regions (Fig. 10). For example, in the cells selected with the NPT mutant Trp91Ala, the gene dose effect is predominant in pool1 while in pool 2 the integration effect dominates. In this way, transfected cells in which markers with a reduced enzyme activity have 2 o been used for the selection are able to synthesise enough marker protein to compensate for the reduced resistance to the selective agent under identical selection pressure.
Example 5: Isolation of cells with high expression of an mAb by GFP-based 2 s FACS sorting In a co-transfection CHO-DG44 cells were transfected with the plasmid combination pBID-HC and pBING-LC, coding for a monoclonal humanised IgG2 antibody (Fig.2B). In the vector confirgurations used the two protein 3 o chains of the antibody are each expressed by their own vector which additionally also codes for a DHFR or modified neomycin phosphotransferase selectable marker (Asp227G1y mutant; SEQ ID N0:21 ) in a separate _ 77 _ transcription unit. In addition, the vector pBING-LC contains another selectable marker, GFP. As a result of the transcriptional linking of the expression of GFP and the light chain by means of an IRES element, on co-transfection of CHO-DG44 with the vectors pBID-HC/pBING-LC it was s possible within a short time to isolate cells with high expression of the monoclonal antibody, purely by selecting the cells with a high GFP content by sequential FACS sorting. In all, 8 separate cell pools were transfected from which after a first two to three weeks selection in HT-free CHO-S-SFMII
medium with the addition of 400 Ng/mL of 6418, stably transfected cell 1 o populations were obtained. The titres and productivities of all 8 pools were determined by ELISA overall several runs (7 - 8). On average the titres were about 1.4 mg/L and the productivities were about 1.3 pg/cell per day. For the subsequent sequential FACS-based sorting the pools 5 and 8 were selected, pool 5 having the highest productivity and pool 8 having a productivity which 15 corresponded to the average of all the pools. In each step, the 5% of cells with the highest GFP fluorescence was sorted out by FACS and further cultivated in the pool. This sorting was carried out up to six times in all, with a cultivation period of about two weeks between each sort. Astonishingly, there was found to be a good correlation between mAb productivity and GFP
2 o fluorescence (Fig. 13), although the two protein chains were each expressed by their own vector and during GFP-based FACS sorting, it was only possible to selecte for the expression of the light chain, as a result of its transcriptional coupling to GFP. The productivities were able to be increased to 9.5 pg/cell/day by FACS-based sorting alone (Fig. 11 ). Comparable data were 2s also obtained when the Hamster Promoter was functionally linked to the SV40-Enhancer instead of the CMV-Enhancer. By a single subsequent MTX
amplification setp, starting from pools 5 and 8 of the first sorting step, by adding 100 nM MTX to the selection medium, it was possible to increase the productivity of the pools to an average of more than 20 pg/cell/day (Fig. 12).
3 o The high expression levels of the fluorescent protein had no negative effects whatever on cell growth and vitality. During gene amplification the growth properties of the cells are also seriously negatively influenced by the addition _ 7g _ of MTX, particularly when it is added in higher cencentrations. However, the pre-sorted cell pools showed considerably more robust characteristics in response to the quiet high initial dose of 100 nM MTX. They withstood the selection phase much better, i.e. after only 2 weeks cell populations were obtained with high vitality and a good growth rate.
In addition, the development time for selecting high producing cells was reduced to about 6 weeks, compared with a conventional stepwise gene amplification strategy which generally comprises 4 amplification stages with 1 o increasing additions of MTX. This was achieved by the combined use of an enrichment of transfected cells with increased expression of the genes of interest, achieved by using a modified NPT-selectable marker with reduced enzyme activity, followed by a GFP-based FACS sorting with a subsequent gene amplification step.

_ 79 _ LITERATURE
Adam, M.A. et al., J Virol 1991, 65, 4985 - 4990 Altschul, S.F. et al., Nucleic Acids Res. 1997, 25, 3389 - 3402 s Altschul, S.F. et al., J Mol Biol 1990, 215, 403 - 410 Ausubel, F.M, et al., Current Protocols in molecular biology. New York Greene Publishing Associates and Wiley-Interscience. 1994 (updated) Blazques, J. et al., Molecular Microbiology 1991, 5(6), 1511 - 1518 Bennett, R.P. et al., BiaTechniques 1998, 24, 478 - 482 ~ o Burk, D.L. et al., Biochemistry 2001, 40 (30), 8756 - 8764 Chalfie, M. et al., Science 1994, 263, 802 - 805 Chamov, S.M. et al., Antibody Fusion Proteins, Wiley-Liss Inc., 1999 Davies, M.V. et al., J Virol 1992, 66, 1924 - 1932 Faisst, S. et al., Nucleic Acids Research 1992, 20, 3 - 26 15 Gish, W. & States, D.J., Nafure Genet. 1993, 3, 266 - 272 Gossen, M. et al., Curr Opi Biotech 1994, 5, 516 - 520 Duch, M. et al., Gene 1990, 95, 285 - 288 Hanson, K.D. et al., Mol Cell Biol 1995, 15(1 ), 45 - 51 Haber, D.A. et al., Somatic Cell Genetics 1982, 8, 499 - 508 2 o Harris et al., Protein Purification : A Practical Approach, Pickwood and Hames, eds., IRL Press, 1995 Hemann, C. et al., DNA Cell Biol 1994, 13 (4), 437 - 445 Hon, W. et al., Cell 1997, 89, 887 - 895 Hu, S. et al., Cancer Res. 1996, 56 (13), 3055 - 3061 2s Huston, C. et al., Proc Natl Acad Sci USA 1988, 85 (16), 5879 - 5883 Jang, S.K. et al., J Virol 1989, 63, 1651 - 1660 Kaufman, R.J., Methods in Enzymology 1990, 185, 537 - 566 Kocabiyik, S. et al., Biochem Biophys Res Commun 1992, 185(3), 925 - 931 Kortt, A.A. et al., Protein Engineering 1997, 10 (4), 423 - 433 3 o Lottspeich F. and Zorbas H. eds., Bioanalytic, Spektrum Akad. Verl., 1998 Lovejoy, B. et al., Science 1993, 259, 1288 - 1293 Madden, T.L. et al., Meth. Enzymol. 1996, 266, 131 - 141;

Monaco, L. et al., Gene 1996, 180, 145 - 15 Morgan, R.A. et al., Nucleic Acids Research 1992, 20, 1293 - 1299 Mosser, D.D. et al., BioTechniques 1997, 22, 150 - 161 Ohshima, Y. et al., J Mol Biol 1987, 195, 247 - 259 s Pack, P. et al., Biotechnology 1993, 11, 1271 - 1277 Pack, P. et al., J Mol Biol 1995, 246 (11 ), 28 - 34 Pelletier, J. et al., Nature 1988, 334, 320 - 325 Perisic, O. et al., Structure 1994, 2, 1217 - 1226 Platt, S.G. et al., Analyt Biochem 1987, 162, 529 - 535 1 o Ramesh, N. et al., Nucleic Acids Research 1996, 24, 2697 - 2700 Sambrook, J., Fritsch, E.F. & Maniatis, T.,Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989 Scopes, R., Protein Purification, Springer Verlag, 1988 Shaw, K.J. et al., Microbiological Reviews 1993, 57(1 ), 138 - 163 15 Simonson, C.C. et al., Proc Natl Acad Sci USA 1983, 80, 2495 - 2499 Sugimoto et al., Biotechnology 1994, 12, 694 - 698 Yenofsky, R.L. et al., Proc Natl Acad Sci USA 1990, 87, 3435 - 3439 Yoshimura, T. et al., FEBS LETTERS 1989, 244(2), 487 - 493 Urlaub, G. et al., Cell 1983, 33, 405 - 412 2 o Werner, R.G. et al., Arzneim.-Forsch.lDrug.Res. 1998, 48, 870 - 880 Wigler, M. et al., Proc Natl Acad Sci USA 1980, 77, 3567 - 3570 Zhang, J. & Madden, T.L. Genome Res. 1997, 7, 649 - 656;

SEQUENCE LISTING
<110> BOEHRINGER INGELHEIM PHARMA GMBH & CO KG
<120> NEW NEOMYCIN-PHOSPHOTRANSFERASE GENES AND METHODS FOR THE SELECTION OF
RECOMBINANT CELLS PRODUCING HIGH LEVELS OF A DESIRED GENE PRODUCT
<130> Case 1-1411 <140>
<141>
<160> 55 <170> PatentIn Ver. 3.1 <210> 1 <211> 795 <212> DNA
<213> Escherichia coli <400> 1 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct toga 795 <210> 2 <211> 264 <212> PRT
<213> Escherichia coli <400> 2 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 3 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant E182G
<400> 3 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcggggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 795 <210> 4 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant E182G
<400> 4 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Gly Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 5 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant W91A
<400> 5 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac gcgctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 795 <210> 6 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant W91A
<400> 6 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Ala Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 7 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant V198G
<400> 7 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat gggggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 795 <210> 8 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant V198G
<400> 8 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Gly Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 9 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D227A
<400> 9 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtgc tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 795 <210> 10 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D227A
<400> 10 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Ala Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 11 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D227V
<400> 11 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtgt tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 795 <210> 12 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D227V
<400> 12 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Val Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 13 <211> 795 l~
<212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D261G
<400> 13 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 ggcgagttct tctga 795 <210> 14 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D261G
<400> 14 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Gly Glu Phe Phe <210> 15 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D261N
<400> 15 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 aacgagttct tctga 795 <210> 16 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D261N

<400> 16 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asn Glu Phe Phe <210> 17 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant F240I
<400> 17 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcatc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 795 <210> 18 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant F240I
<400> 18 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Ile Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 19 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant E182D
<400> 19 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgatgatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 7g5 <210> 20 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant E182D
<400> 20 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Asp Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 21 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D227G
<400> 21 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtgg tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 795 <210> 22 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D227G
<400> 22 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Gly Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 23 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D190G
<400> 23 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcggt gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 795 <210> 24 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D190G
<400> 24 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Gly Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Asp Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 25 <211> 795 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D208G
<400> 25 atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180 caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac 540 ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 ggccgctttt ctggattcat cggctgtggc cggctgggtg tggcggaccg ctatcaggac 660 atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 gacgagttct tctga 795 <210> 26 <211> 264 <212> PRT
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Neomycin mutant D208G
<400> 26 Met Ile Glu Gln Asp Gly Leu His Ala Gly Ser Pro Ala Ala Trp Val Glu Arg Leu Phe Gly Tyr Asp Trp Ala Gln Gln Thr Ile Gly Cys Ser Asp Ala Ala Val Phe Arg Leu Ser Ala Gln Gly Arg Pro Val Leu Phe Val Lys Thr Asp Leu Ser Gly Ala Leu Asn Glu Leu Gln Asp Glu Ala Ala Arg Leu Ser Trp Leu Ala Thr Thr Gly Val Pro Cys Ala Ala Val Leu Asp Val Val Thr Glu Ala Gly Arg Asp Trp Leu Leu Leu Gly Glu Val Pro Gly Gln Asp Leu Leu Ser Ser His Leu Ala Pro Ala Glu Lys Val Ser Ile Met Ala Asp Ala Met Arg Arg Leu His Thr Leu Asp Pro Ala Thr Cys Pro Phe Asp His Gln Ala Lys His Arg Ile Glu Arg Ala Arg Thr Arg Met Glu Ala Gly Leu Val Asp Gln Asp Asp Leu Asp Glu Glu His Gln Gly Leu Ala Pro Ala Glu Leu Phe Ala Arg Leu Lys Ala Ser Met Pro Asp Gly Glu Asp Leu Val Val Thr His Gly Asp Ala Cys Leu Pro Asn Ile Met Val Glu Asn Gly Arg Phe Ser Gly Phe Ile Gly Cys Gly Arg Leu Gly Val Ala Asp Arg Tyr Gln Asp Ile Ala Leu Ala Thr Arg Asp Ile Ala Glu Glu Leu Gly Gly Glu Trp Ala Asp Arg Phe Leu Val Leu Tyr Gly Ile Ala Ala Pro Asp Ser Gln Arg Ile Ala Phe Tyr Arg Leu Leu Asp Glu Phe Phe <210> 27 <211> 21 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide Neofor5 <400> 27 ttccagaagt agtgaggagg c 21 <210> 28 <211> 19 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide Neorev5 <400> 28 atggcaggtt gggcgtcgc 19 <210> 29 <211> 21 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide Neofor2 <400> 29 gaactgttcg ccaggctcaa g 21 <210> 30 <211> 22 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide IC49 <400> 30 cggcaaaatc ccttataaat ca 22 <210> 31 <211> 20 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide E182Gfor <400> 31 gacggcgggg atctcgtcgt 20 <210> 32 <211> 20 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide E182Grev <400> 32 acgacgagat ccccgccgtc 20 <210> 33 <211> 23 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide W9lAfor <400> 33 gggaagggac gcgctgctat tgg 23 <210> 34 <211> 23 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide W9lArev <400> 34 ccaatagcag cgcgtccctt ccc 23 <210> 35 <211> 24 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide V198Gfor <400> 35 ccgaatatca tgggggaaaa tggc 24 <210> 36 <211> 24 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide V198Grev <400> 36 gccattttcc cccatgatat tcgg 24 <210> 37 <211> 21 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D227Afor <400> 37 ctacccgtgc tattgctgaa g 21 <210> 38 <211> 21 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D227Arev <400> 38 cttcagcaat agcacgggta g 21 <210> 39 <211> 21 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D227Vfor <400> 39 ctacccgtgt tattgctgaa g 21 <210> 40 <211> 21 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D227Vrev <400> 40 cttcagcaat aacacgggta g 21 <210> 41 <211> 24 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D261Gfor <400> 41 gccttcttgg cgagttcttc tgag 24 <210> 42 <211> 24 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D261Grev <400> 42 ctcagaagaa ctcgccaaga aggc 24 <210> 43 <211> 24 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D261Nfor <400> 43 gccttcttaa cgagttcttc tgag 24 <210> 44 <211> 24 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D261Nrev <400> 44 ctcagaagaa ctcgttaaga aggc 24 <210> 45 <211> 22 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide F240Ifor <400> 45 ggctgaccgc atcctcgtgc tt 22 <210> 46 <211> 22 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide F240Irev <400> 46 aagcacgagg atgcggtcag cc 22 <210> 47 <211> 20 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotid E182Dfor <400> 47 gacggcgatg atctcgtcgt 20 <210> 48 <211> 20 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide E182Drev <400> 48 acgacgagat catcgccgtc 20 <210> 49 <211> 19 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D190Gfor <400> 49 catggcggtg cctgcttgc 19 <210> 50 <211> 19 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D190Grev <400> 50 gcaagcaggc accgccatg 19 <210> 51 <211> 19 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D208Gfor <400> 51 gattcatcgg ctgtggccg 19 <210> 52 <211> 19 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D208Grev <400> 52 cggccacagc cgatgaatc 19 <210> 53 <211> 21 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D227Gfor <400> 53 ctacccgtgg tattgctgaa g 21 <210> 54 <211> 21 <212> DNA
<213> Artificial sequence <220>
<223> Description of the artificial sequence:
Oligonucleotide D227Grev <400> 54 cttcagcaat accacgggta g 21 <210> 55 <211> 2406 <212> DNA
<213> Cricetulus griseus <300>
<310> PCT/EP/96/04631 <311> 1996-10-24 <312> 1997-05-01 <400> 55 gatctccagg acagccatgg ctattacaca gagaaaccct gtctggaaaa acaaaaaatt 60 agtgtccatg tgtaaatgtg tggagtatgc ttgtcatgcc acatacagag gtagagggca 120 gtttatggga gtcagttcct attcttcctt tatgggggac ctggggactg aactcaggtc 180 atcaggcttg gcagaaagtg cattagctca cggagcctta tcattggcga aagctctctc 240 aagtagaaaa tcaatgtgtt tgctcatagt gcaatcatta tgtttcgaga ggggaagggt 300 acaatcgttg gggcatgtgt ggtcacatct gaatagcagt agctccctag gagaattcca 360 agttctttgg tggtgtatca atgcccttaa aggggtcaac aacttttttt ccctctgaca 420 aaactatctt cttatgtcct tgtccctcat atttgaagta ttttattctt tgcagtgttg 480 aatatcaatt ctagcacctc agacatgtta ggtaagtacc ctacaactca ggttaactaa 540 tttaatttaa ctaatttaac cccaacactt tttctttgtt tatccacatt tgtggagtgt 600 gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgc 660 gcgcgcgcgc gcgctcggat cattctacct tttgtttaaa aaatgttagt ccaggggtgg 720 ggtgcactgt gaaagtctga gggtaacttg ctggggtcag ttctttccac tataggacag 780 aactccaggt gtcaactctt tactgacaga accatccaaa tagccctatc taattttagt 840 tttttattta tttatttttt gtttttcgag acagggtttc tctgtggctt tggaggctgt 900 cctggaacta gctcttgtag accaggctgg tctcgaactc agagatccac ctgcctctgc 960 ctcctgagtg ctgggattaa aggcatgcgc caccaacgct tggctctacc taattttaaa 1020 agagattgtg tgtcacaagg gtgtcatgtc gccctgcaac cacccccccc ccaaaaaaaa 1080 aaaaaaaaaa acttcactga agctgaagca cgatgatttg gttactctgg ctggccaatg 1140 agctctaggg agtctcctgt caaacagaat ctcaacaggc gcagcagtct tttttaaagt 1200 ggggttacaa cacaggtttt tgcatatcag gcattttatc taagctattt cccagccaaa 1260 aatgtgtatt ttggaggcag cagagctaat agattaaaat gagggaagag cccacacagg 1320 ttattaggaa gataagcatc ttctttatat aaaacaaaac caaaccaaac tggaggaggt 1380 ctacctttag ggatggaaga aaagacattt agagggtgca atagaaaggg cactgagttt 1440 gtgaggtgga ggactgggag agggcgcaac cgctttaact gtcctgtttt gcctattttt 1500 tggggacagc acatgttcct atttttccca ggatgggcaa tctccacgtc caaacttgcg 1560 gtcgaggact acagtcattt tgcaggtttc cttactgtat ggcttttaaa acgtgcaaag 1620 gtgaccatta accgtttcac gctgggaggg cacgtgcggc tcagatgctt cctctgactg 1680 agggccagga gggggctaca cggaagaggc cacacccgca cttgggaaga ctcgatttgg 1740 gcttcagctg gctgagacgc cccagcaggc tcctcggcta caccttcagc cccgaatgcc 1800 ttccggccca taacccttcc cttctaggca tttccggcga ggacccaccc tcgcgccaaa 1860 cattcggccc catcccccgg tcctcacctg aatctctaac tctgactcca gagtttagag 1920 actataacca gatagcccgg atgtgtggaa ctgcatcttg ggacgagtag ttttagcaaa 1980 aagaaagcga cgaaaaacta caattcccag acagacttgt gttacctctc ttctcatgct 2040 aaacaagccc cctttaaagg aaagcccctc ttagtcgcat cgactgtgta agaaaggcgt 2100 ttgaaacatt ttaatgttgg gcacaccgtt tcgaggaccg aaatgagaaa gagcataggg 2160 aaacggagcg cccgagctag tctggcactg cgttagacag ccgcggtcgt tgcagcgggc 2220 aggcacttgc gtggacgcct aaggggcggg tctttcggcc gggaagcccc gttggtccgc 2280 gcggctcttc ctttccgatc cgccatccgt ggtgagtgtg tgctgcgggc tgccgctccg 2340 gcttggggct tcccgcgtcg ctctcaccct ggtcggcggc tctaatccgt ctcttttcga 2400 atgtag 2406

Claims (43)

1. Modified neomycin phosphotransferase gene characterised in that the modified neomycin phosphotransferase gene at amino acid position 91, 198 and/or 240 in relation to the wild-type gene codes for a different amino acid than the wild-type neomycin phosphotransferase gene.
2. Modified neomycin phosphotransferase gene according to claim 1, characterised in that the modified neomycin phosphotransferase which is encoded by the neomycin phosphotransferase gene has a lower enzyme activity than the wild-type neomycin phosphotransferase.
3. Modified neomycin phosphotransferase gene according to claim 1 or 2 characterised in that the modified neomycin phosphotransferase gene compared with the wild-type gene codes for alanine at amino acid position 91 in relation to the wild-type gene, for glycine at amino acid position 198, and/or for isoleucine at amino acid position 240.
4. Modified neomycin phosphotransferase gene according to one of claims 1 to 3 characterised in that the modified neomycin phosphotransferase gene codes for a polypeptide with an amino acid sequence according to SEQ
ID NO:6, SEQ SEQ ID NO:8 or SEQ ID NO:18.
5. Modified neomycin phosphotransferase gene according to one of claims 1 to 4 containing or consisting of a sequence according to SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO:17.
6. Modified neomycin phosphotransferase gene characterised in that the modified neomycin phosphotransferase gene compared with the wild-type gene codes for glycine at amino acid position 182 in relation to the wild-type gene, for alanine or valine at amino acid position 227 and/or for glycine at amino acid position 261.
7. Modified neomycin phosphotransferase gene according to claim 6 characterised in that the modified neomycin phosphotransferase gene codes for a polypeptide with an amino acid sequence according to SEQ
ID NO:4, SEQ ID NO:10, SEQ ID NO:12 or SEQ ID NO:14.
8. Modified neomycin phosphotransferase gene according to one of claims 6 or 7 containing or consisting of a sequence according to SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:13.
9. Modified neomycin phosphotransferase encoded by a modified neomycin phosphotransferase gene according to one of claims 1 to 8.
10. Eukaryotic expression vector containing a modified neomycin phosphotransferase gene according to one of claims 1 to 8.
11. Eukaryotic expression vector containing a heterologous gene of interest functionally linked to a heterologous promoter and a modified neomycin phosphotransferase gene which codes for a neomycin phosphotransferase having a lower enzyme activity compared with wild-type neomycin phosphotransferase.
12. Expression vector according to claim 11, characterised in that a) the modified neomycin phosphotransferase gene is a gene according to one of claims 1 to 5, or b) the modified neomycin phosphotransferase gene at amino acid position 182 and/or 227 codes for a different amino acid than the wild-type gene at the corresponding site, or c) the modified neomycin phosphotransferase gene at amino acid position 261 codes for a glycine.
13. Expression vector according to claim 12, characterised in that by comparison with the wild-type gene the modified neomycin phosphotransferase gene at amino acid position 182 codes for glycine or aspartic acid and/or by comparison with the wild-type gene at amino acid position 227 it codes for an alanine, glycine or valine.
14. Expression vector according to claim 12, characterised in that the modified neomycin phosphotransferase gene codes for a protein with an amino acid sequence according to SEQ ID NO:4, SEQ ID NO:6, SEQ ID
NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:18, SEQ ID:20 or SEQ ID NO:22.
15. Expression vector according to one of claims 12 to 14, characterised in that it contains one or more enhancers functionally linked to the promoter or promoters.
16. Expression vector according to claim 15 characterised in that the enhancer is a CMV or SV40 enhancer.
17. Expression vector according to one of claims 11 to 16 characterised in that it contains a hamster ubiquitin/S27a promotor.
18. Expression vector according to claim 17 characterised in that the heterologous gene of interest is under the control of the ubiquitin/S27a promoter.
19. Expression vector according to one of claims 11 to 18 characterised in that it additionally contains a gene for a fluorescent protein which is/will optionally be functionally linked to the gene of interest and the heterologous promoter.
20. Expression vector according to claim 19, characterised in that it additionally contains an internal ribosome entry site (IRES) which enables bicistronic expression of the gene which codes for a fluorescent protein, and of the gene which codes for a protein/product of interest, under the control of a heterologous promoter.
21. Expression vector according to claim 19 or 20, characterised in that the gene which codes for a fluorescent protein, and the modified neomycin-phosphotransferase gene are located in one or in two separate transcription units.
22. Mammalian cell containing a modified neomycin phosphotransferase gene according to one of claims 1 to 8.
23. Mammalian cell which has been transfected with an expression vector according to one of Claims 10 to 18.
24. Mammalian cell which has been transfected with an expression vector according to one of Claims 19 to 21.
25. Mammalian cell according to one of claims 22 to 24, characterised in that it has additionally been transfected with a gene for an amplifiable selectable marker.
26. Mammalian cell according to claim 25, characterised in that the amplifiable selectable marker gene is dihydrofolate-reductase (DHFR).
27. Mammalian cell according to one of claims 22 to 26, characterised in that the mammalian cell is a rodent cell.
28. Mammalian cell according to claim 27, characterised in that the rodent cell is a CHO or BHK cell.
29. Method of enriching mammalian cells, characterised in that (i) a pool of mammalian cells is transfected with a gene for a modified neomycin-phosphotransferase according to one of claims 1 to 8 or with an E182D, D227G or D261N neomycin phosphotransferase mutant;
(ii) the mammalian cells are cultivated under conditions which allow expression of the modified neomycin-phosphotransferase gene; and (iii) the mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells, and gives preference to the growth of those cells which express the modified neomycin-phosphotransferase gene.
30. Method of obtaining and selecting mammalian cells which express at least one heterologous gene of interest, characterised in that (i) a pool of mammalian cells is transfected with at least one gene of interest and a gene for a modified neomycin-phosphotransferase according to one of claims 1 to 8 or with an E182D, D227G or D261N
neomycin phosphotransferase mutant;
(ii) the mammalian cells are cultivated under conditions which allow expression of the gene or genes of interest and of the modified neomycin-phosphotransferase gene; and (iii) the mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells, and gives preference to the growth of those cells which express the modified neomycin-phosphotransferase gene.
31. Method according to claim 30, characterised in that the mammalian cells are additionally transfected with a gene for an amplifiable selectable marker and the selected mammalian cells are preferably subjected to at least one gene amplification step, the amplifiable selectable marker gene preferably being DHFR and the gene amplification preferably being carried out by the addition of methotrexate.
32. Method of obtaining and selecting mammalian cells which express at least one heterologous gene of interest, characterised in that (i) recombinant mammalian cells are transformed with an expression vector according to one of Claims 19 to 21;
(ii) are cultivated under conditions which allow expression of the gene (or genes) of interest, of the gene which codes for a fluorescent protein, and of the modified neomycin-phosphotransferase gene;
(iii) the mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells, and gives preference to the growth of those cells which express the modified neomycin-phosphotransferase gene; and (iv) the mammalian cells are sorted by flow-cytometric analysis.
33. Method according to claim 32, characterised in that the mammalian cells are additionally transfected with a gene for an amplifiable selectable marker and the cells sorted by flow-cytometric analysis are subjected to at least one gene amplification step, the amplifiable selectable marker gene preferably being DHFR and the gene amplification preferably being carried out by the addition of methotrexate.
34. Method of producing at least one protein of interest in recombinant mammalian cells, characterised in that (i) a pool of mammalian cells is transfected with at least one gene of interest and one gene for a modified neomycin-phosphotransferase according to one of claims 1 to 8 or with an E182D, D227G or D261N
neomycin phosphotransferase mutant;
(ii) the cells are cultivated under conditions which allow expression of the gene (or genes) of interest and of the modified neomycin-phosphotransferase;

(iii) the mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells, and gives preference to the growth of those cells which express the modified neomycin-phosphotransferase gene; and (iv) the protein(s) of interest is or are obtained from the mammalian cells or the culture supernatant.
35. Method of producing at least one protein of interest in recombinant mammalian cells, characterised in that (i) recombinant mammalian cells are transformed with an expression vector according to one of Claims 19 to 21;
(ii)are cultivated under conditions which allow expression of the gene (or genes) of interest, of the gene which codes for a fluorescent protein, and of the modified neomycin-phosphotransferase gene;
(iii) the mammalian cells are cultivated in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells, and gives preference to the growth of those cells which express the modified neomycin-phosphotransferase gene; and (iv) the mammalian cells are sorted by flow-cytometric analysis (v) the proteins) of interest is (are) obtained from the mammalian cells or the culture supernatant.
36. Method of producing at least one protein of interest, characterised in that (i) mammalian cells according to one of Claims 25 or 26 are cultivated under conditions which allow expression of the gene of interest, of the modified neomycin-phosphotransferase gene and of the amplifiable selectable marker gene;
(ii) the mammalian cells are cultivated and selected in the presence of at least one selecting agent which acts selectively on the growth of mammalian cells, and gives preference to the growth of those cells which express the modified neomycin-phosphotransferase gene;

(iii) the selected mammalian cells are subjected to at least one gene amplification step; and (iv) the protein(s) of interest is or are subsequently obtained from the mammalian cells or the culture supernatant.
37. Method according to one of Claims 34 to 36, characterised in that the mammalian cells are transfected with at least two genes of interest which code for a heteromeric protein/product, and (i) are cultivated under conditions which allow expression of the subunits of the heteromeric protein/product; and (ii) the heteromeric protein/product is isolated from the culture or culture medium.
38. Method according to one of Claims 34 to 37, characterised in that the sorted mammalian cells exhibit an average specific productivity of more than 5pg of the desired gene product (or products) per day and per cell.
39. Method according to claim 36 or 37, characterised in that the sorted host cells exhibit an average specific productivity of more than 20pg of the desired gene product (or products) per day and per cell.
40. Method according to one of Claims 29 to 39, characterised in that the mammalian cell is a rodent cell.
41. Method according to Claim 40, characterised in that the rodent cell is a CHO or BHK cell.
42. Method according to one of Claims 29 to 41, characterised in that the mammalian cells are cultivated in suspension culture.
43. Method according to one of Claims 29 to 42, characterised in that the mammalian cells are cultivated serum-free.
CA2507664A 2002-11-29 2003-11-25 Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product Expired - Lifetime CA2507664C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2706873A CA2706873C (en) 2002-11-29 2003-11-25 Modified neomycin-phosphotransferase gene that increases expression rates of co-integrated gene and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10256081 2002-11-29
DE10256081.1 2002-11-29
DE10330686A DE10330686A1 (en) 2002-11-29 2003-07-08 New neomycin phosphotransferase genes and methods for the selection of high-producing recombinant cells
DE10330686.2 2003-07-08
PCT/EP2003/013203 WO2004050884A2 (en) 2002-11-29 2003-11-25 Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2706873A Division CA2706873C (en) 2002-11-29 2003-11-25 Modified neomycin-phosphotransferase gene that increases expression rates of co-integrated gene and uses thereof

Publications (2)

Publication Number Publication Date
CA2507664A1 CA2507664A1 (en) 2004-06-17
CA2507664C true CA2507664C (en) 2010-09-07

Family

ID=32471486

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2507664A Expired - Lifetime CA2507664C (en) 2002-11-29 2003-11-25 Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product

Country Status (12)

Country Link
EP (1) EP1567652B1 (en)
JP (1) JP4344325B2 (en)
KR (1) KR101149777B1 (en)
AT (1) ATE371035T1 (en)
AU (1) AU2003302689B2 (en)
BR (1) BR0316525A (en)
CA (1) CA2507664C (en)
DE (1) DE50308030D1 (en)
DK (1) DK1567652T3 (en)
ES (1) ES2293096T3 (en)
MX (1) MXPA05005481A (en)
WO (1) WO2004050884A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
FR2897068B1 (en) * 2006-02-03 2008-04-18 Biomethodes Sa IMPROVED KANAMYCINE KINASE II AND USES THEREOF
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP1975228A1 (en) * 2007-03-28 2008-10-01 Fachhochschule Mannheim Polynucleotides for enhancing expression of a polynucleotide of interest
ES2552325T3 (en) 2008-12-22 2015-11-27 National University Corporation Hokkaido University Expression vector for large-scale production of protein derived from foreign genes using animal cells, and use thereof
JP4525863B1 (en) * 2009-06-05 2010-08-18 東洋紡績株式会社 Expression vector for establishment of high-productivity cells and high-productivity cells
JP4547643B1 (en) * 2009-06-05 2010-09-22 東洋紡績株式会社 Expression vector optimized for cloning
JP4491808B1 (en) * 2009-06-05 2010-06-30 東洋紡績株式会社 Drug selection marker gene expression cassette useful for efficient selection of high-expressing cells
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
JP5775974B2 (en) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド Humanized antibodies that recognize alpha synuclein
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
EP2859103B1 (en) 2012-06-06 2019-04-17 Boehringer Ingelheim International GmbH CELL ENGINEERING USING RNAs
UA118441C2 (en) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Antibodies recognizing alpha-synuclein
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
PE20152004A1 (en) 2013-03-13 2016-02-07 Prothena Biosciences Ltd IMMUNOTHERAPY TAU
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015075635A2 (en) 2013-11-19 2015-05-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
TW201623331A (en) 2014-03-12 2016-07-01 普羅帝納生物科學公司 Anti-MCAM antibodies and associated methods of use
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
KR20160131082A (en) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Anti-laminin4 antibodies specific for lg1-3
PT3116911T (en) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anti-mcam (cd146, muc16) antibodies and associated methods of use
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI769570B (en) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI718122B (en) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI718121B (en) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
CU24537B1 (en) 2016-05-02 2021-07-02 Prothena Biosciences Ltd MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 3D6 ANTIBODY
PE20190208A1 (en) 2016-05-02 2019-02-07 Prothena Biosciences Ltd ANTIBODIES THAT RECOGNIZE TAU
KR102506091B1 (en) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 Tau Immunotherapy
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478716A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (en) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
US20190352631A1 (en) * 2016-11-16 2019-11-21 Agency For Science Technology And Research Attenuated Glutamine Synthetase as a Selection Marker
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
WO2019064053A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
KR20210094610A (en) 2018-11-26 2021-07-29 포티 세븐, 인코포레이티드 Humanized Antibodies to c-Kit
JP2022524588A (en) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド Tau recognition antibody
US20240026350A1 (en) * 2020-04-07 2024-01-25 Io Biosciences, Inc. Nucleic acid constructs comprising gene editing multi-sites

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04179485A (en) * 1990-11-09 1992-06-26 Junichi Miyazaki New vector and method for selecting highly expressing transformed cell using the same vector
JP2004179485A (en) 2002-11-28 2004-06-24 Matsushita Electric Ind Co Ltd Printed wiring board and method of manufacturing the same

Also Published As

Publication number Publication date
WO2004050884A2 (en) 2004-06-17
AU2003302689B2 (en) 2009-02-05
KR20050085202A (en) 2005-08-29
JP2006507842A (en) 2006-03-09
WO2004050884A3 (en) 2004-07-15
EP1567652A2 (en) 2005-08-31
AU2003302689A1 (en) 2004-06-23
ATE371035T1 (en) 2007-09-15
MXPA05005481A (en) 2005-07-25
EP1567652B1 (en) 2007-08-22
KR101149777B1 (en) 2012-06-11
BR0316525A (en) 2005-10-04
JP4344325B2 (en) 2009-10-14
DE50308030D1 (en) 2007-10-04
DK1567652T3 (en) 2007-11-26
ES2293096T3 (en) 2008-03-16
CA2507664A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
CA2507664C (en) Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
US8338179B2 (en) Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
US20090162900A1 (en) Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such of such products
US9708626B2 (en) Regulatory nucleic acid elements
CA2507714A1 (en) Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
CA2706873C (en) Modified neomycin-phosphotransferase gene that increases expression rates of co-integrated gene and uses thereof
NZ540851A (en) Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells
NZ540950A (en) Expression vector, methods for the production of heterologous gene products, and selection method for high-producing recombinant cells

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20231127